US 2016O193212A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0193212 A1 Rao et al. (43) Pub. Date: Jul. 7, 2016

(54) CYCLOPROPYL MODULATORS OF P2Y12 (52) U.S. Cl. RECEPTOR CPC ...... A61 K3I/519 (2013.01); A61K 45/06 (2013.01) (71) Applicant: Auspex Pharmaceuticals, Inc., La Jolla, (57) ABSTRACT CA (US) The present invention relates to new cyclopropyl modulators O O of P2Y 12 receptor activity, pharmaceutical compositions (72) Inventors: Tadimeti Rao, San Diego, CA (US); thereof, and methods of use thereof. Chengzhi Zhang, San Diego, CA (US)

(21) Appl. No.: 14/977,056 Formula I

(22) Filed: Dec. 21, 2015

Related U.S. Application Data (60) Continuation of application No. 14/299,782, filed on Jun. 9, 2014, now Pat. No. 9,255,104, which is a divi sion of application No. 12/844,017, filed on Jul. 27. 2010, now Pat. No. 8,802,850. (60) Provisional application No. 61/228,913, filed on Jul. 27, 2009.

Publication Classification (51) Int. Cl. R25 R24 A63/59 (2006.01) A6 IK 45/06 (2006.01) US 2016/01932 12 A1 Jul. 7, 2016

CYCLOPROPYL MODULATORS OF P2Y12 most drugs, such oxidations are generally rapid and ulti RECEPTOR mately lead to administration of multiple or high daily doses. 0001. This application is a continuation of U.S. patent 0006. The relationship between the activation energy and application Ser. No. 14/299,782, filed Jun. 9, 2014, which is a the rate of reaction may be quantified by the Arrhenius equa division of U.S. patent application Ser. No. 12/844,017, filed tion, k=Ae'. The Arrhenius equation states that, at a Jul. 27, 2010, which claims the benefit of priority of U.S. given temperature, the rate of a chemical reaction depends provisional application No. 61/228,913, filed Jul. 27, 2009, exponentially on the activation energy (E). the disclosures of which are hereby incorporated by reference 0007. The transition state in a reaction is a short lived state as if written herein in their entireties. along the reaction pathway during which the original bonds 0002 Disclosed herein are new substituted cyclopropyl have stretched to their limit. By definition, the activation compounds, pharmaceutical compositions made thereof, and energy Eact for a reaction is the energy required to reach the methods to modulate P2Y 12 receptor activity in a subject are transition state of that reaction. Once the transition state is also provided for, for the treatment of disorders such as arte reached, the molecules can either revert to the original reac rial thrombosis and coronary artery disease. tants, or form new bonds giving rise to reaction products. A 0003. Ticagrelor (AR-C126532, AZD-6140, BrilintaR), catalyst facilitates a reaction process by lowering the activa CAS #274693-27-5), 3-7-1R,2S)-2-(3,4-difluorophenyl) tion energy leading to a transition state. Enzymes are cyclopropylamino-5-(propylthio)-3H-1,2,3-triazolo 4.5-d examples of biological catalysts. pyrimidin-3-yl)-5-(2-hydroxyethoxy)-(1S,2S,3R,5S)-1,2- 0008 Carbon-hydrogen bond strength is directly propor cyclopentanediol, is a P2Y12 receptor antagonist. Ticagrelor tional to the absolute value of the ground-state vibrational is currently under investigation for the treatment of arterial energy of the bond. This vibrational energy depends on the thrombosis (Tantry et al., Exp. Opin. Invest. Drugs 2007, mass of the atoms that form the bond, and increases as the 16(2), 225-229; Husted et al., Eur: Heart J. 2006, 27(9), mass of one or both of the atoms making the bond increases. 1038-1047; and WO 2000034283). Ticagrelor has also shown Since deuterium (D) has twice the mass of protium ("H), a promise in treating coronary artery disease and other disor C-D bond is stronger than the corresponding C-H bond. If a ders related to platelet aggregation (Tantry et al., Exp. Opin. C-H bond is broken during a rate-determining step in a chemical reaction (i.e. the step with the highest transition Invest. Drugs 2007, 16(2), 225-229; Husted et al., Eur: Heart state energy), then Substituting a deuterium for that protium J. 2006, 27(9), 1038-1047; and WO 2000034283). will cause a decrease in the reaction rate. This phenomenon is known as the Deuterium Kinetic Isotope Effect (DKIE). The magnitude of the DKIE can be expressed as the ratio between the rates of a given reaction in which a C-H bond is broken, and the same reaction where deuterium is substituted for protium. The DKIE can range from about 1 (no isotope effect) to very large numbers, such as 50 or more. Substitution of tritium for hydrogen results in yet a stronger bond than deu terium and gives numerically larger isotope effects I0009 Deuterium (H or D) is a stable and non-radioactive isotope of hydrogen which has approximately twice the mass of protium ("H), the most common isotope of hydrogen. Deuterium oxide (DO or “heavy water) looks and tastes like HO, but has different physical properties. 0010 When pure DO is given to rodents, it is readily Ticagrelor absorbed. The quantity of deuterium required to induce tox icity is extremely high. When about 0-15% of the body water has been replaced by DO, animals are healthy but are unable 0004 Ticagrelor is subject to CYP450-mediated oxidative to gain weight as fast as the control (untreated) group. When metabolism, forming an active metabolite AR-C124910XX about 15-20% of the body water has been replaced with D.O. (Husted et al., Eur: Heart J. 2006, 27, 1038-1047). Adverse the animals become excitable. When about 20-25% of the effects associated with ticagrelor include excessive bleeding. body water has been replaced with DO, the animals become so excitable that they go into frequent convulsions when Deuterium Kinetic Isotope Effect stimulated. Skin lesions, ulcers on the paws and muzzles, and 0005. In order to eliminate foreign substances such as necrosis of the tails appear. The animals also become very therapeutic agents, the animal body expresses various aggressive. When about 30% of the body water has been enzymes, such as the cytochrome Paso enzymes (CYPs), replaced with DO, the animals refuse to eat and become esterases, proteases, reductases, dehydrogenases, and comatose. Their body weight drops sharply and their meta monoamine oxidases, to react with and convert these foreign bolic rates drop far below normal, with death occurring at Substances to more polar intermediates or metabolites for about 30 to about 35% replacement with D.O.The effects are renal excretion. Such metabolic reactions frequently involve reversible unless more than thirty percent of the previous the oxidation of a carbon-hydrogen (C-H) bond to either a body weight has been lost due to D.O. Studies have also carbon-oxygen (C-O) or a carbon-carbon (C-C) JU-bond. shown that the use of DO candelay the growth of cancer cells The resultant metabolites may be stable or unstable under and enhance the cytotoxicity of certain antineoplastic agents. physiological conditions, and can have Substantially different 0011 Deuteration of pharmaceuticals to improve pharma pharmacokinetic, pharmacodynamic, and acute and long cokinetics (PK), pharmacodynamics (PD), and toxicity pro term toxicity profiles relative to the parent compounds. For files has been demonstrated previously with some classes of US 2016/01932 12 A1 Jul. 7, 2016

drugs. For example, the DKIE was used to decrease the hepa 0015. In certain embodiments of the present invention, totoxicity of halothane, presumably by limiting the produc compounds have structural Formula I: tion of reactive species such as trifluoroacetylchloride. How ever, this method may not be applicable to all drug classes. For example, deuterium incorporation can lead to metabolic (I) Switching. Metabolic Switching occurs when Xenogens, sequestered by Phase I enzymes, bind transiently and re-bind in a variety of conformations prior to the chemical reaction (e.g., oxidation). Metabolic switching is enabled by the rela tively vast size of binding pockets in many Phase I enzymes and the promiscuous nature of many metabolic reactions. Metabolic switching can lead to different proportions of known metabolites as well as altogether new metabolites. This new metabolic profile may impart more or less toxicity. Such pitfalls are non-obvious and are not predictable a priori for any drug class. 0012 Ticagrelor is a P2Y 12 receptor antagonist. The car bon-hydrogen bonds of ticagrelor contain a naturally occur ring distribution of hydrogen isotopes, namely Horprotium (about 99.984.4%), Hordeuterium (about 0.0156%), and H or tritium (in the range between about 0.5 and 67 tritium atoms per 10' protium atoms). Increased levels of deuterium incorporation may produce a detectable Deuterium Kinetic or a pharmaceutically acceptable salt thereof, wherein: Isotope Effect (DKIE) that could effect the pharmacokinetic, pharmacologic and/or toxicologic profiles of ticagrelor in 0016 R-Rs are independently selected from the group comparison with ticagrelor having naturally occurring levels consisting of hydrogen and deuterium; and of deuterium. I0017 at least one of R-Rs is deuterium. 0018 Certain compounds disclosed herein may possess 0013 Based on discoveries made in our laboratory, as well useful P2Y 12 receptor modulating activity, and may be used as considering the literature, ticagrelor is likely metabolized in the treatment or prophylaxis of a disorder in which P2Y 12 in humans at the 2-hydroxyethoxy group, the S-propyl group, receptors play an active role. Thus, certain embodiments also and the cyclopropyl group. The current approach has the provide pharmaceutical compositions comprising one or potential to prevent metabolism at these sites. Other sites on more compounds disclosed herein together with a pharma the molecule may also undergo transformations leading to ceutically acceptable carrier, as well as methods of making metabolites with as-yet-unknown pharmacology/toxicology. and using the compounds and compositions. Certain embodi Limiting the production of these metabolites has the potential ments provide methods for modulating P2Y 12 receptor activ to decrease the danger of the administration of such drugs and ity. Other embodiments provide methods for treating a P2Y 12 may even allow increased dosage and/or increased efficacy. receptor-mediated disorder in a patient in need of such treat All of these transformations can occur through polymorphi ment, comprising administering to said patient a therapeuti cally-expressed enzymes, exacerbating interpatient variabil cally effective amount of a compound or composition accord ity. Further, some disorders are best treated when the subject ing to the present invention. Also provided is the use of certain is medicated around the clock or for an extended period of compounds disclosed herein for use in the manufacture of a time. For all of the foregoing reasons, a medicine with a medicament for the prevention or treatment of a disorder longer half-life may result in greater efficacy and cost sav ameliorated by modulating P2Y 12 receptor activity. ings. Various deuteration patterns can be used to (a) reduce or 0019. The compounds as disclosed herein may also con eliminate unwanted metabolites, (b) increase the half-life of tain less prevalent isotopes for other elements, including, but the parent drug, (c) decrease the number of doses needed to not limited to, C or “C for carbon, S, S, or S for sulfur, achieve a desired effect, (d) decrease the amount of a dose 'N for nitrogen, and ''O or 'O for oxygen. needed to achieve a desired effect, (e) increase the formation 0020. In certain embodiments, the compound disclosed of active metabolites, if any are formed, (f) decrease the herein may expose a patient to a maximum of about production of deleterious metabolites in specific tissues, and/ 0.000005% DO or about 0.00001% DHO, assuming that all or (g) create a more effective drug and/or a safer drug for of the C-D bonds in the compound as disclosed herein are polypharmacy, whether the polypharmacy be intentional or metabolized and released as DO or DHO. In certain embodi not. The deuteration approach has the strong potential to slow ments, the levels of DO shown to cause toxicity in animals is the metabolism of ticagrelor and attenuate interpatient vari much greater than even the maximum limit of exposure ability. caused by administration of the deuterium enriched com 0014 Novel compounds and pharmaceutical composi pound as disclosed herein. Thus, in certain embodiments, the tions, certain of which have been found to modulate P2Y 12 deuterium-enriched compound disclosed herein should not receptor activity have been discovered, together with meth cause any additional toxicity due to the formation of DO or ods of synthesizing and using the compounds, including DHO upon drug metabolism. methods for the treatment of P2Y 12 receptor-mediated dis 0021. In certain embodiments, the deuterated compounds orders in a patient by administering the compounds as dis disclosed herein maintain the beneficial aspects of the corre closed herein. sponding non-isotopically enriched molecules while Substan US 2016/01932 12 A1 Jul. 7, 2016 tially increasing the maximum tolerated dose, decreasingtox 0031 Asymmetric centers exist in the compounds dis icity, increasing the half-life (T), lowering the maximum closed herein. These centers are designated by the symbols plasma concentration (C) of the minimum efficacious “R” or “S”, depending on the configuration of substituents dose (MED), lowering the efficacious dose and thus decreas around the chiral carbon atom. It should be understood that ing the non-mechanism-related toxicity, and/or lowering the the invention encompasses all Stereochemical isomeric probability of drug-drug interactions. forms, including diastereomeric, enantiomeric, and epimeric 0022 All publications and references cited herein are forms, as well as D-isomers and L-isomers, and mixtures expressly incorporated herein by reference in their entirety. thereof. Individual stereoisomers of compounds can be pre However, with respect to any similar or identical terms found pared synthetically from commercially available starting in both the incorporated publications or references and those materials which contain chiral centers or by preparation of explicitly put forth or defined in this document, then those mixtures of enantiomeric products followed by separation terms definitions or meanings explicitly put forthin this docu such as conversion to a mixture of diastereomers followed by ment shall control in all respects. separation or recrystallization, chromatographic techniques, 0023. As used herein, the terms below have the meanings direct separation of enantiomers on chiral chromatographic indicated. columns, or any other appropriate method known in the art. Starting compounds of particular Stereochemistry are either 0024. The singular forms “a”, “an', and “the may refer to commercially available or can be made and resolved by tech plural articles unless specifically stated otherwise. niques known in the art. Additionally, the compounds dis 0025. The term “about’, as used herein, is intended to closed herein may exist as geometric isomers. The present qualify the numerical values which it modifies, denoting Such invention includes all cis, trans, syn, anti, entgegen (E), and a value as variable within a margin of error. When no particu Zusammen (Z) isomers as well as the appropriate mixtures lar margin of error, such as a standard deviation to a mean thereof. Additionally, compounds may exist as tautomers; all value given in a chart or table of data, is recited, the term tautomeric isomers are provided by this invention. Addition “about’ should be understood to mean that range which ally, the compounds disclosed herein can exist in unsolvated would encompass the recited value and the range which as well as Solvated forms with pharmaceutically acceptable would be included by rounding up or down to that figure as Solvents such as water, ethanol, and the like. In general, the well, taking into account significant figures. Solvated forms are considered equivalent to the unsolvated 0026. When ranges of values are disclosed, and the nota forms. tion “from n ... to n' or “n-n” is used, where n and n are 0032. The term “bond” refers to a covalent linkage the numbers, then unless otherwise specified, this notation is between two atoms, or two moieties when the atoms joined by intended to include the numbers themselves and the range the bond are considered to be part of larger substructure. A between them. This range may be integral or continuous bond may be single, double, or triple unless otherwise speci between and including the end values. fied. A dashed line between two atoms in a drawing of a 0027. The term “deuterium enrichment” refers to the per molecule indicates that an additional bond may be present or centage of incorporation of deuterium at a given position in a absent at that position. molecule in the place of hydrogen. For example, deuterium 0033. The term “disorder as used herein is intended to be enrichment of 1% at a given position means that 1% of mol generally synonymous, and is used interchangeably with, the ecules in a given sample contain deuterium at the specified terms “disease”, “syndrome', and “condition' (as in medical position. Because the naturally occurring distribution of deu condition), in that all reflect an abnormal condition of the terium is about 0.0156%, deuterium enrichment at any posi human or animal body or of one of its parts that impairs tion in a compound synthesized using non-enriched starting normal functioning, is typically manifested by distinguishing materials is about 0.0156%. The deuterium enrichment can signs and Symptoms. be determined using conventional analytical methods known 0034. The terms “treat”, “treating, and “treatment” are to one of ordinary skill in the art, including mass spectrometry meant to include alleviating or abrogating a disorder or one or and nuclear magnetic resonance spectroscopy. more of the symptoms associated with a disorder; or allevi 0028. The term “is/are deuterium', when used to describe ating or eradicating the cause(s) of the disorder itself. As used a given position in a molecule such as R-Rs or the symbol herein, reference to “treatment of a disorder is intended to “D’, when used to represent a given position in a drawing of include prevention. The terms “prevent”, “preventing, and a molecular structure, means that the specified position is “prevention” refer to a method of delaying or precluding the enriched with deuterium above the naturally occurring distri onset of a disorder; and/or its attendant symptoms, barring a bution of deuterium. In one embodiment deuterium enrich Subject from acquiring a disorder or reducing a subject’s risk ment is no less than about 1%, in another no less than about of acquiring a disorder. 5%, in another no less than about 10%, in another no less than 0035. The term “therapeutically effective amount” refers about 20%, in another no less than about 50%, in another no to the amount of a compound that, when administered, is less than about 70%, in another no less than about 80%, in sufficient to prevent development of, or alleviate to some another no less than about 90%, or in another no less than extent, one or more of the symptoms of the disorder being about 98% of deuterium at the specified position. treated. The term “therapeutically effective amount” also 0029. The term “isotopic enrichment” refers to the per refers to the amount of a compound that is sufficient to elicit centage of incorporation of a less prevalent isotope of an the biological or medical response of a cell, tissue, system, element at a given position in a molecule in the place of the animal, or human that is being sought by a researcher, Veteri more prevalent isotope of the element. narian, medical doctor, or clinician. 0030 The term “non-isotopically enriched’ refers to a 0036. The term “subject” refers to an animal, including, molecule in which the percentages of the various isotopes are but not limited to, a primate (e.g., human, monkey, chimpan Substantially the same as the naturally occurring percentages. Zee, gorilla, and the like), rodents (e.g., rats, mice, gerbils, US 2016/01932 12 A1 Jul. 7, 2016

hamsters, ferrets, and the like), lagomorphs, Swine (e.g., pig, forms, etc.) which are suitable for use in contact with the miniature pig), equine, canine, feline, and the like. The terms tissues of patients without excessive toxicity, irritation, aller “subject' and “patient” are used interchangeably herein in gic response, immunogenecity, are commensurate with a rea reference, for example, to a mammalian Subject, such as a sonable benefit/risk ratio, and are effective for their intended human patient. US 0037. The term “combination therapy’ means the admin 0042. The term “pharmaceutically acceptable carrier, istration of two or more therapeutic agents to treat a thera “pharmaceutically acceptable excipient”, “physiologically peutic disorder described in the present disclosure. Such acceptable carrier, or “physiologically acceptable excipi administration encompasses co-administration of these ent” refers to a pharmaceutically-acceptable material, com therapeutic agents in a Substantially simultaneous manner, position, or vehicle, such as a liquid or Solid filler, diluent, Such as in a single capsule having a fixed ratio of active excipient, Solvent, or encapsulating material. Each compo ingredients or in multiple, separate capsules for each active nent must be “pharmaceutically acceptable' in the sense of ingredient. In addition, Such administration also encom being compatible with the other ingredients of a pharmaceu passes use of each type of therapeutic agent in a sequential tical formulation. It must also be suitable for use in contact manner. In either case, the treatment regimen will provide with the tissue or organ of humans and animals without exces beneficial effects of the drug combination in treating the sive toxicity, irritation, allergic response, immunogenecity, or disorders described herein. other problems or complications, commensurate with a rea 0038. The term “P2Y 12 receptor” refers to a G-protein sonable benefit/risk ratio. See, Remington. The Science and coupled receptor located on the platelet membrane. The Practice of Pharmacy, 21st Edition; Lippincott Williams & P2Y12 receptor (also known as P2T, P2YADP, or P2TAC) is Wilkins: Philadelphia, Pa., 2005, Handbook of Pharmaceu primarily involved in mediating platelet aggregation/activa tical Excipients, 5th Edition; Rowe et al., Eds. The Pharma tion. The pharmacological characteristics of this receptor ceutical Press and the American Pharmaceutical Association: have been described, for example, by Humphries et al., Br. J. 2005; and Handbook of Pharmaceutical Additives, 3rd Edi Pharmacology 1994, 113, 1057-1063; and Fagura et al., Br. J. tion; Ash and Ash Eds. Gower Publishing Company: 2007; Pharmacology 1998, 124, 157-164. Pharmaceutical Preformulation and Formulation, Gibson 0039. The term “P2Y12 receptor-mediated disorder, Ed., CRC Press LLC: Boca Raton, Fla., 2004). refers to a disorder that is characterized by abnormal P2Y 12 0043. The terms “active ingredient”, “active compound', receptor activity or excessive platelet aggregation, or normal and “active substance' refer to a compound, which is admin platelet aggregation or normal P2Y 12 receptor activity that istered, alone or in combination with one or more pharma when modulated ameliorates other abnormal biochemical ceutically acceptable excipients or carriers, to a Subject for processes. A P2Y 12 receptor-mediated disorder may be com treating, preventing, or ameliorating one or more symptoms pletely or partially mediated by modulating P2Y 12 receptor of a disorder. activity. In particular, a P2Y 12 receptor-mediated disorder is 0044) The terms “drug”,99 “therapeutic&g agent, and “chemo one in which modulation of P2Y 12 receptor activity results in therapeutic agent” refer to a compound, or a pharmaceutical Some effect on the underlying disorder e.g., administration of composition thereof, which is administered to a subject for a P2Y 12 receptor modulator results in some improvement in treating, preventing, or ameliorating one or more symptoms at least some of the patients being treated. of a disorder. 0040. The term “P2Y 12 receptor modulator', refers to the 0045. The term “release controlling excipient” refers to an ability of a compound disclosed hereinto alter the function of excipient whose primary function is to modify the duration or P2Y 12 receptors. A P2Y 12 receptor modulator may activate place of release of the active Substance from a dosage form as the activity of a P2Y 12 receptor, may activate or inhibit the compared with a conventional immediate release dosage activity of a P2Y 12 receptor depending on the concentration form. of the compound exposed to the P2Y 12 receptor, or may 0046. The term “nonrelease controlling excipient” refers inhibit the activity of a P2Y 12 receptor. Such activation or to an excipient whose primary function do not include modi inhibition may be contingent on the occurrence of a specific fying the duration or place of release of the active Substance event. Such as activation of a signal transduction pathway, from a dosage form as compared with a conventional imme and/or may be manifest only in particular cell types. The term diate release dosage form. “P2Y 12 receptor modulator, also refers to altering the func 0047. The term “prodrug” refers to a compound functional tion of a P2Y 12 receptor by increasing or decreasing the derivative of the compound as disclosed herein and is readily probability that a complex forms between a P2Y 12 receptor convertible into the parent compound in vivo. Prodrugs are and a natural binding partner. A P2Y 12 receptor modulator often useful because, in Some situations, they may be easier to may increase the probability that such a complex forms administer than the parent compound. They may, for instance, between the P2Y 12 receptor and the natural binding partner, be bioavailable by oral administration whereas the parent may increase or decrease the probability that a complex forms compound is not. The prodrug may also have enhanced solu between the P2Y 12 receptor and the natural binding partner bility in pharmaceutical compositions over the parent com depending on the concentration of the compound exposed to pound. A prodrug may be converted into the parent drug by the P2Y 12 receptor, and or may decrease the probability that various mechanisms, including enzymatic processes and a complex forms between the P2Y 12 receptor and the natural metabolic hydrolysis. See Harper, Progress in Drug Research binding partner. In some embodiments, modulation of the 1962, 4, 221–294; Morozowich et al. in “Design of Biophar P2Y 12 receptor activity may be assessed using the method maceutical Properties through Prodrugs and Analogs. Roche described in Husted et al., Eur: Heart J. 2006, 27(9), 1038 Ed., APHA Acad. Pharm. Sci. 1977: “Bioreversible Carriers 1047; WO 2000034283; WO 199905142. in Drug in Drug Design, Theory and Application. Roche Ed., 0041. The term “therapeutically acceptable” refers to APHA Acad. Pharm. Sci. 1987: “Design of Prodrugs.” Bund those compounds (or salts, prodrugs, tautomers, Zwitterionic gaard, Elsevier, 1985; Wang et al., Curr: Pharm. Design 1999, US 2016/01932 12 A1 Jul. 7, 2016

5,265-287: Pauletti et al., Adv. Drug. Delivery Rev. 1997,27, 0050 Suitable bases for use in the preparation of pharma 235-256; Mizen et al., Pharm. Biotech. 1998, 11, 345-365; ceutically acceptable salts, including, but not limited to, inor Gaignault et al., Pract. Med. Chem. 1996, 671-696; ganic bases, such as magnesium hydroxide, calcium hydrox Asgharnejad in “Transport Processes in Pharmaceutical Sys ide, potassium hydroxide, Zinc hydroxide, or Sodium tems. Amidon et al., Ed., Marcell Dekker, 185-218, 2000; hydroxide; and organic bases, such as primary, secondary, Balant et al., Eur: J. Drug Metab. Pharmacokinet. 1990, 15, tertiary, and quaternary, aliphatic and aromatic amines, 143-53; Balimane and Sinko, Adv. Drug Delivery Rev. 1999, including L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, 39, 183-209; Browne, Clin. Neuropharmacol. 1997, 20, 1-12; dipropylamine, diisopropylamine, 2-(diethylamino)-ethanol, Bundgaard, Arch. Pharm. Chem. 1979, 86, 1-39: Bundgaard, ethanolamine, ethylamine, ethylenediamine, isopropy Controlled Drug Delivery 1987, 17, 179–96: Bundgaard, Adv. lamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, Drug Delivery Rev. 1992, 8, 1-38; Fleisher et al., Adv. Drug L-lysine, morpholine, 4-(2-hydroxyethyl)-morpholine, Delivery Rev. 1996, 19, 115-130; Fleisher et al., Methods methylamine, piperidine, piperazine, propylamine, pyrroli Enzymol. 1985, 112,360-381: Farquhar et al., J. Pharm. Sci. dine, 1-(2-hydroxyethyl)-pyrrolidine, pyridine, quinuclidine, 1983, 72, 324-325; Freeman et al., J. Chem. Soc., Chem. quinoline, isoquinoline, secondary amines, triethanolamine, Commun. 1991, 875-877: Friis and Bundgaard, Eur: J. trimethylamine, triethylamine, N-methyl-D-glucamine, Pharm. Sci. 1996, 4, 49-59; Gangwar et al., Des. Biopharm. 2-amino-2-(hydroxymethyl)-1,3-propanediol. and Prop. Prodrugs Analogs, 1977, 409–421; Nathwani and tromethamine. Wood, Drugs 1993, 45,866-94: Sinhababu and Thakker, Adv. Drug Delivery Rev. 1996, 19, 241-273; Stella et al., Drugs 0051 While it may be possible for the compounds of the 1985, 29, 455-73; Tan et al., Adv. Drug Delivery Rev. 1999, Subject invention to be administered as the raw chemical, it is 39, 117-151; Taylor, Adv. Drug Delivery Rev. 1996, 19, 131 also possible to present them as a pharmaceutical composi 148; Valentino and Borchardt, Drug Discovery Today 1997.2, tion. Accordingly, provided herein are pharmaceutical com 148-155; Wiebe and Knaus, Adv. Drug Delivery Rev. 1999, positions which comprise one or more of certain compounds 39, 63-80; Waller et al., Br. J. Clin. Pharmac. 1989, 28, disclosed herein, or one or more pharmaceutically acceptable 497-507. salts, prodrugs, or Solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally 0048. The compounds disclosed herein can exist as thera one or more other therapeutic ingredients. Properformulation peutically acceptable salts. The term “pharmaceutically is dependent upon the route of administration chosen. Any of acceptable salt as used herein, represents salts or Zwitteri the well-known techniques, carriers, and excipients may be onic forms of the compounds disclosed herein which are used as Suitable and as understood in the art; e.g., in Reming therapeutically acceptable as defined herein. The salts can be ton’s Pharmaceutical Sciences. The pharmaceutical compo prepared during the final isolation and purification of the sitions disclosed herein may be manufactured in any manner compounds or separately by reacting the appropriate com known in the art, e.g., by means of conventional mixing, pound with a suitable acid or base. Therapeutically accept dissolving, granulating, dragee-making, levigating, emulsi able salts include acid and basic addition salts. For a more fying, encapsulating, entrapping or compression processes. complete discussion of the preparation and selection of salts, The pharmaceutical compositions may also be formulated as refer to “Handbook of Pharmaceutical Salts, Properties, and a modified release dosage form, including delayed-, Use.” Stah and Wermuth, Ed. (Wiley-VCH and VHCA, Zur extended-, prolonged-, Sustained-, pulsatile-, controlled ich, 2002) and Berge et al., J. Pharm. Sci. 1977, 66, 1-19. accelerated- and fast-, targeted-, programmed-release, and 0049 Suitable acids for use in the preparation of pharma gastric retention dosage forms. These dosage forms can be ceutically acceptable salts include, but are not limited to, prepared according to conventional methods and techniques acetic acid, 2,2-dichloroacetic acid, acylated amino acids, known to those skilled in the art (see, Remington. The Science adipic acid, alginic acid, ascorbic acid, L-aspartic acid, ben and Practice of Pharmacy, supra; Modified-Release Drug Zenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, Deliver Technology, Rathbone et al., Eds. Drugs and the boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)- Pharmaceutical Science, Marcel Dekker, Inc.: New York, (1S)-camphor-10-Sulfonic acid, capric acid, caproic acid, N.Y., 2002; Vol. 126). caprylic acid, cinnamic acid, citric acid, cyclamic acid, cyclo 0.052 The compositions include those suitable for oral, hexanesulfamic acid, dodecylsulfuric acid, ethane-1,2-disul parenteral (including Subcutaneous, intradermal, intramuscu fonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic lar, intravenous, intraarticular, and intramedullary), intraperi acid, formic acid, fumaric acid, galactaric acid, gentisic acid, toneal, transmucosal, transdermal, rectal and topical (includ glucoheptonic acid, D-gluconic acid, D-glucuronic acid, ing dermal, buccal, Sublingual and intraocular) L-glutamic acid, C-OXO-glutaric acid, glycolic acid, hippuric administration although the most Suitable route may depend acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, upon for example the condition and disorder of the recipient. (+)-L-lactic acid, (t)-DL-lactic acid, lactobionic acid, lauric The compositions may conveniently be presented in unit dos acid, maleic acid, (-)-L-malic acid, malonic acid, (+)-DL age form and may be prepared by any of the methods well mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic known in the art of pharmacy. Typically, these methods acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naph include the step of bringing into association a compound of thoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, the Subject invention or a pharmaceutically salt, prodrug, or oxalic acid, palmitic acid, pamoic acid, perchloric acid, phos solvate thereof (“active ingredient') with the carrier which phoric acid, L-pyroglutamic acid, Saccharic acid, salicylic constitutes one or more accessory ingredients. In general, the acid, 4-amino-salicylic acid, sebacic acid, Stearic acid, suc compositions are prepared by uniformly and intimately cinic acid, Sulfuric acid, tannic acid, (+)-L-tartaric acid, thio bringing into association the active ingredient with liquid cyanic acid, p-toluenesulfonic acid, undecylenic acid, and carriers or finely divided solid carriers or both and then, if Valeric acid. necessary, shaping the product into the desired formulation. US 2016/01932 12 A1 Jul. 7, 2016

0053 Formulations of the compounds disclosed herein ides, or liposomes. Aqueous injection Suspensions may con Suitable for oral administration may be presented as discrete tain Substances which increase the Viscosity of the Suspen units such as capsules, cachets or tablets each containing a Sion, such as Sodium carboxymethyl cellulose, Sorbitol, or predetermined amount of the active ingredient; as a powder or dextran. Optionally, the Suspension may also contain Suitable granules; as a solution or a suspension in an aqueous liquid or stabilizers or agents which increase the solubility of the com a non-aqueous liquid; or as an oil-in-water liquid emulsion or pounds to allow for the preparation of highly concentrated a water-in-oil liquid emulsion. The active ingredient may also Solutions. be presented as a bolus, electuary or paste. 0057. In addition to the formulations described previously, 0054 Pharmaceutical preparations which can be used the compounds may also be formulated as a depot prepara orally include tablets, push-fit capsules made of gelatin, as tion. Such long acting formulations may be administered by well as Soft, sealed capsules made of gelatin and a plasticizer, implantation (for example Subcutaneously or intramuscu Such as glycerol or Sorbitol. Tablets may be made by com larly) or by intramuscular injection. Thus, for example, the pression or molding, optionally with one or more accessory compounds may be formulated with Suitable polymeric or ingredients. Compressed tablets may be prepared by com hydrophobic materials (for example as an emulsion in an pressing in a suitable machine the active ingredient in a free acceptable oil) or ion exchange resins, or as sparingly soluble flowing form such as a powder or granules, optionally mixed derivatives, for example, as a sparingly soluble salt. with binders, inert diluents, or lubricating, surface active or 0.058 Forbuccal or sublingual administration, the compo dispersing agents. Molded tablets may be made by molding in sitions may take the form of tablets, lozenges, pastilles, or a suitable machine a mixture of the powdered compound gels formulated in conventional manner. Such compositions moistened with an inert liquid diluent. The tablets may may comprise the active ingredient in a flavored basis such as optionally be coated or scored and may be formulated so as to Sucrose and acacia or tragacanth. provide slow or controlled release of the active ingredient 0059. The compounds may also be formulated in rectal therein. All formulations for oral administration should be in compositions such as Suppositories or retention enemas, e.g., dosages suitable for Such administration. The push-fit cap containing conventional Suppository bases such as cocoa but Sules can contain the active ingredients in admixture with ter, polyethylene glycol, or other glycerides. filler Such as lactose, binders such as starches, and/or lubri cants such as talc or magnesium Stearate and, optionally, 0060 Certain compounds disclosed herein may be admin stabilizers. In soft capsules, the active compounds may be istered topically, that is by non-systemic administration. This dissolved or suspended in Suitable liquids, such as fatty oils, includes the application of a compound disclosed herein liquid paraffin, or liquid polyethylene glycols. In addition, externally to the epidermis or the buccal cavity and the instil stabilizers may be added. Dragee cores are provided with lation of such a compound into the ear, eye and nose, such that Suitable coatings. For this purpose, concentrated Sugar Solu the compound does not significantly enter the blood stream. tions may be used, which may optionally contain gum arabic, In contrast, Systemic administration refers to oral, intrave talc, polyvinyl pyrrolidone, carbopol gel, polyethylene gly nous, intraperitoneal and intramuscular administration. col, and/or titanium dioxide, lacquer Solutions, and Suitable 0061 Formulations suitable for topical administration organic solvents or solvent mixtures. Dyestuffs or pigments include liquid or semi-liquid preparations Suitable for pen may be added to the tablets or dragee coatings for identifica etration through the skin to the site of inflammation Such as tion or to characterize different combinations of active com gels, liniments, lotions, creams, ointments or pastes, and pound doses. drops suitable for administration to the eye, ear or nose. 0055. The compounds may be formulated for parenteral 0062 For administration by inhalation, compounds may administration by injection, e.g., by bolus injection or con be delivered from an insufflator, nebulizer pressurized packs tinuous infusion. Formulations for injection may be presented or other convenient means of delivering an aerosol spray. in unit dosage form, e.g., in ampoules or in multi-dose con Pressurized packs may comprise a suitable propellant Such as tainers, with an added preservative. The compositions may dichlorodifluoromethane, trichlorofluoromethane, dichlo take Such forms as Suspensions, solutions or emulsions in oily rotetrafluoroethane, carbon dioxide or other suitable gas. In or aqueous vehicles, and may contain formulatory agents the case of a pressurized aerosol, the dosage unit may be Such as Suspending, stabilizing and/or dispersing agents. The determined by providing a valve to deliver a metered amount. formulations may be presented in unit-dose or multi-dose Alternatively, for administration by inhalation or insufflation, containers, for example sealed ampoules and vials, and may the compounds according to the invention may take the form be stored in powder form or in a freeze-dried (lyophilized) ofa dry powder composition, for example a powder mix of the condition requiring only the addition of the sterile liquid compound and a suitable powder base such as lactose or carrier, for example, saline or sterile pyrogen-free water, starch. The powder composition may be presented in unit immediately prior to use. Extemporaneous injection solu dosage form, in for example, capsules, cartridges, gelatin or tions and Suspensions may be prepared from sterile powders, blister packs from which the powder may be administered granules and tablets of the kind previously described. with the aid of an inhalator or insufflator. 0056. Formulations for parenteral administration include 0063 Preferred unit dosage formulations are those con aqueous and non-aqueous (oily) sterile injection Solutions of taining an effective dose, as herein below recited, oran appro the active compounds which may contain antioxidants, buff priate fraction thereof, of the active ingredient. ers, bacteriostats and solutes which render the formulation 0064 Compounds may be administered orally or via isotonic with the blood of the intended recipient; and aqueous injection at a dose of from 0.1 to 500 mg/kg per day. The dose and non-aqueous sterile Suspensions which may include Sus range for adult humans is generally from 5 mg to 2 g/day. pending agents and thickening agents. Suitable lipophilic Tablets or other forms of presentation provided in discrete Solvents or vehicles include fatty oils such as sesame oil, or units may conveniently contain an amount of one or more synthetic fatty acid esters, such as ethyl oleate or triglycer compounds which is effective at Such dosage or as a multiple US 2016/01932 12 A1 Jul. 7, 2016 of the same, for instance, units containing 5 mg to 500 mg. as myeloproliferative disease, including thrombocythaemia, usually around 10 mg to 200 mg. sickle cell disease; or in the prevention of mechanically 0065. The amount of active ingredient that may be com induced platelet activation in vivo. Such as cardio-pulmonary bined with the carrier materials to produce a single dosage bypass and extracorporeal membrane oxygenation (preven form will vary depending upon the host treated and the par tion of microthromboembolism), mechanically-induced ticular mode of administration. platelet activation in vitro, Such as use in the preservation of 0066. The compounds can be administered in various blood products, e.g. platelet concentrates, or shunt occlusion modes, e.g. orally, topically, or by injection. The precise Such as in renal dialysis and plasmapheresis, thrombosis sec amount of compound administered to a patient will be the ondary to vascular damage/inflammation Such as vasculitis, responsibility of the attendant physician. The specific dose arteritis, glomerulonephritis, inflammatory bowel disease level for any particular patient will depend upon a variety of and organ graft rejection, conditions such as migraine, factors including the activity of the specific compound Raynaud's phenomenon, conditions in which platelets can employed, the age, body weight, general health, sex, diets, contribute to the underlying inflammatory disease process in time of administration, route of administration, rate of excre the vascular wall Such as atheromatous plaque formation/ tion, drug combination, the precise disorder being treated, progression, Stenosis/restenosis, in other inflammatory con and the severity of the disorder being treated. Also, the route ditions such as asthma, in which platelets and platelet-derived of administration may vary depending on the disorder and its factors are implicated in the immunological disease process, severity. and/or any disorder which can lessened, alleviated, or pre 0067. In the case wherein the patient’s condition does not vented by administering a P2Y 12 receptor modulator. improve, upon the doctor's discretion the administration of 0072. In certain embodiments, a method of treating a the compounds may be administered chronically, that is, for P2Y 12 receptor-mediated disorder comprises administering an extended period of time, including throughout the duration to the subject a therapeutically effective amount of a com of the patient’s life in order to ameliorate or otherwise control pound as disclosed herein, or a pharmaceutically acceptable or limit the symptoms of the patient’s disorder. salt, Solvate, or prodrug thereof. So as to affect: (1) decreased 0068. In the case wherein the patient’s status does inter-individual variation in plasma levels of the compound or improve, upon the doctor's discretion the administration of a metabolite thereof; (2) increased average plasma levels of the compounds may be given continuously or temporarily the compound or decreased average plasma levels of at least Suspended for a certain length of time (i.e., a "drug holiday'). one metabolite of the compound per dosage unit; (3) 0069. Once improvement of the patient’s conditions has decreased inhibition of, and/or metabolism by at least one occurred, a maintenance dose is administered if necessary. cytochrome P450 or monoamine oxidase isoform in the sub Subsequently, the dosage or the frequency of administration, ject; (4) decreased metabolism via at least one polymorphi or both, can be reduced, as a function of the symptoms, to a cally-expressed cytochrome P450 isoform in the subject; (5) level at which the improved disorder is retained. Patients can, at least one statistically-significantly improved disorder-con however, require intermittent treatment on a long-term basis trol and/or disorder-eradication endpoint; (6) an improved upon any recurrence of symptoms. clinical effect during the treatment of the disorder, (7) pre 0070 Disclosed herein are methods of treating a P2Y 12 vention of recurrence, or delay of decline or appearance, of receptor-mediated disorder comprising administering to a abnormal alimentary or hepatic parameters as the primary Subject having or Suspected of having Such a disorder, a clinical benefit, or (8) reduction or elimination of deleterious therapeutically effective amount of a compound as disclosed changes in any diagnostic hepatobiliary function endpoints, herein or a pharmaceutically acceptable salt, Solvate, or pro as compared to the corresponding non-isotopically enriched drug thereof. compound. (0071 P2Y12 receptor-mediated disorders, include, but 0073. In certain embodiments, inter-individual variation are not limited to, arterial thrombosis, coronary artery dis in plasma levels of the compounds as disclosed herein, or ease, myocardial infarction, stroke, atherosclerosis, acute metabolites thereof, is decreased; average plasma levels of coronary syndrome, peripheral artery occlusive disease, the compound as disclosed herein are increased; average carotid, vertebral, or intracerebral artery stenosis, unstable plasma levels of a metabolite of the compound as disclosed angina, primary arterial thrombotic complications of athero herein are decreased; inhibition of a cytochrome P450 or Sclerosis Such as thrombotic or embolic stroke, transient monoamine oxidase isoform by a compound as disclosed ischaemic attacks, peripheral vascular disease, myocardial herein is decreased; or metabolism of the compound as dis infarction with or without thrombolysis, arterial complica closed herein by at least one polymorphically-expressed tions due to interventions in atherosclerotic disease such as cytochrome P450 isoform is decreased; by greater than about angioplasty, including coronary angioplasty (PTCA), endar 5%, greater than about 10%, greater than about 20%, greater terectomy, stent placement, coronary and other vascular graft than about 30%, greater than about 40%, or by greater than Surgery, thrombotic complications of Surgical or mechanical about 50% as compared to the corresponding non-isotopi damage such as tissue salvage following accidental or Surgi cally enriched compound. cal trauma, reconstructive Surgery including skin and muscle 0074 Plasma levels of the compound as disclosed herein, flaps, conditions with a diffuse thrombotic/platelet consump or metabolites thereof, may be measured using the methods tion component such as disseminated intravascular coagula described by Li et al. Rapid Communications in Mass Spec tion, thrombotic thrombocytopaenic purpura, haemolytic trometry 2005, 19, 1943-1950; Butler, et al., Drug Metab Rev uraemic syndrome, thrombotic complications of septicaemia, 2008, 40(Suppl. 3): Abst 280; Husted et al., European Heart adult respiratory distress syndrome, anti-phospholipid syn Journal 2006, 27(9), 1038-1047; and any references cited drome, heparin-induced thrombocytopaenia and pre-eclamp therein and any modifications made thereof. sia/eclampsia, or venous thrombosis such as deep vein throm 0075 Examples of cytochrome Paso isoforms in a mam bosis, Venoocclusive disease, haematological conditions such malian subject include, but are not limited to, CYP1A1, US 2016/01932 12 A1 Jul. 7, 2016

CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, have minimal therapeutic benefit, but in combination with CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, another therapeutic agent, the overall therapeutic benefit to CYP2E1, CYP2G1 CYP2J2, CYP2R1, CYP2S1, CYP3A4, the patient is enhanced). CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, 0084. Such other agents, adjuvants, or drugs, may be administered, by a route and in an amount commonly used therefor, simultaneously or sequentially with a compound as disclosed herein. When a compound as disclosed herein is CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, used contemporaneously with one or more other drugs, a CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, and pharmaceutical composition containing such other drugs in CYP51. addition to the compound disclosed herein may be utilized, 0076 Examples of monoamine oxidase isoforms in a but is not required. mammalian Subject include, but are not limited to, MAO I0085. In certain embodiments, the compounds disclosed and MAO. herein can be combined with one or more alpha adrenergic 0077. The inhibition of the cytochrome P450 isoform is receptor antagonists, beta-adrenergic antagonists, angio measured by the method of Ko et al., British Journal of tensin II receptor antagonists, angiotensin-converting Clinical Pharmacology 2000, 49,343-351. The inhibition of enzyme inhibitors, anti-arrhythmics, antithrombotics, anti the MAO isoform is measured by the method of Weyler et platelet agents, calcium channel blockers, fibrates, and HMG al., J. Biol Chem. 1985, 260, 13199-13207. The inhibition of CoA reductase inhibitors. the MAO isoform is measured by the method of Uebelhack I0086. In certain embodiments, the compounds disclosed et al., Pharmacopsychiatry, 1998, 31, 187-192. herein can be combined with one or more alpha adrenergic 0078 Examples of polymorphically-expressed cyto receptor antagonists known in the art, including, but not lim chrome Paso isoforms in a mammalian Subject include, but are ited to, abanoquil, adimolol, ajmalicine, alfuZosin, amoSula not limited to, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. lol, arotinolol, atiprosin, benoxathian, buflomedil, bunaZosin, 007.9 The metabolic activities of liver microsomes, cyto carvedilol, CI-926, corynanthine, dapiprazole, DL-017, chrome Paso isoforms, and monoamine oxidase isoforms are domesticine, doxazosin, eugenodilol, fenspiride, GYKI-12, measured by the methods described herein. 743, GYKI-16,084, indoramin, ketanserin, L-765,314, labe 0080 Examples of improved disorder-control and/or dis talol, mephendioxan, metazosin, monatepil, moxisylyte (thy order-eradication endpoints, or improved clinical effects moxamine), naftopidil, nantenine, neldaZosin, nicergoline, include, but are not limited to, bleeding time, platelet inhibi niguldipine, pelanserin, phendioxan, phenoxybenzamine, tion, inhibition of adenosine-5'-diphosphate-induced platelet phentolamine, piperoxan, prazosin, quinaZosin, ritanserin, aggregation as measured by optical aggregometry of platelet RS-97.078, SGB-1,534, silodosin, SL-89.0591, spiperone, rich plasma, reduced cardiovascular death, reduced myocar talipexole, tamsulosin, teraZosin, tibalosin, tiodaZosin, tipen dial infarction, reduced stroke, and reduced bleeding events tosin, tolazoline, trimaZosin, upidosin, urapidil. Zolertine, (Tantry et al., Exp. Opin. Invest. Drugs 2007, 16(2), 225-229; 1-PP. adimolol, atipamezole, BRL-44408, buflomedil, cira Husted et al., Eur: Heart J. 2006, 27(9), 1038-1047; and WO Zoline, efaroxan, esmirtazapine, fluparoxan, GYKI-12,743, 2000034283). GYKI-16,084, idazoxan, mianserin, mirtazapine, MK-912, 0081 Examples of diagnostic hepatobiliary function end NAN-190, olanzapine, phentolamine, phenoxybenzamine, points include, but are not limited to, alanine aminotrans piperoxan, piribedil, rauwolscine, rotigotine, SB-269,970, ferase (ALT), serum glutamic-pyruvic transaminase setiptiline, SpiroXatrine, Sunepitron, tolaZoline, and yohim (“SGPT), aspartate aminotransferase (AST or “SGOT), bine. ALT/AST ratios, serum aldolase, alkaline phosphatase I0087. In certain embodiments, the compounds disclosed (ALP), ammonia levels, bilirubin, gamma-glutamyl herein can be combined with one or more beta-adrenergic transpeptidase (“GGTP” “Y-GTP or “GGT), leucine ami antagonists, including, but not limited to, acebutolol. nopeptidase (“LAP), liver biopsy, liver ultrasonography, adaprolol, adimolol, afurolol, alprenolol, alprenoXime, amo liver nuclear Scan, 5'-nucleotidase, and blood protein. Hepa Sulalol, ancarolol, arnolol, arotinolol, atenolol, befunolol. tobiliary endpoints are compared to the stated normal levels betaxolol, bevantolol, bisoprolol, bopindolol, bormetolol, as given in “Diagnostic and Laboratory Test Reference', 4' bornaprolol, brefonalol, bucindolol, bucumolol, bufetolol, edition, Mosby, 1999. These assays are run by accredited buftiralol, bufuralol, bunitrolol, bunolol, bupranolol, buro laboratories according to standard protocol. crolol, butaxamine, butidrine, butofilolol, cap sinolol, cara 0082 Besides being useful for human treatment, certain Zolol, carpindolol, carteolol, carvedilol, celiprolol, ceta compounds and formulations disclosed herein may also be molol, cicloprolol, cinamolol, cloranolol, cyanopindolol. useful for veterinary treatment of companion animals, exotic dalbraminol, dexpropranolol, diacetolol, dichloroisoprena animals and farm animals, including mammals, rodents, and line, dihydroalprenolol, dilevalol, diprafenone, draquinolol. the like. More preferred animals include horses, dogs, and dropranolol, ecastolol, epanolol, ericolol, ersentilide, Cats. esatenolol, esmolol, esprolol, eugenodilol, exaprolol, falin tolol, flestolol, flusoxolol, hydroxycarteolol, hydroxyterta tolol, ICI-118.551, idropranolol, indenolol, indopanolol, Combination Therapy iodocyanopindolol, iprocrolol, isoxaprolol, isamoltane, labe 0083. The compounds disclosed herein may also be com talol, landiolol, levobetaxolol, levobunolol, levocicloprolol, bined or used in combination with other agents useful in the levomoprolol, medroxalol, mepindolol, metalol, metipra treatment of P2Y 12 receptor-mediated disorders. Or, by way nolol, metoprolol, moprolol, nadolol, nadoxolol, nafetolol. of example only, the therapeutic effectiveness of one of the nebivolol, neraminol, nifenalol, nipradillol, oberadillol, Oxpre compounds described herein may be enhanced by adminis nolol, pacrinolol, pafenolol, pamatolol, pargolol, parodilol. tration of an adjuvant (i.e., by itself the adjuvant may only penbutolol, penirolol, PhOA-33, pindolol, pirepolol, prac US 2016/01932 12 A1 Jul. 7, 2016 tolol, primidolol, procinolol, pronethalol, propafenone, pro tolol, flestolol, flusoxolol, hydroxycarteolol, hydroxyterta pranolol, ridazolol, ronactolol, Soquinolol, Sotalol, spiren tolol, ICI-118.551, idropranolol, indenolol, indopanolol, dolol, SR 59230A, sulfinalol, TA-2005, tallinolol, tazolol, iodocyanopindolol, iprocrolol, isoxaprolol, isamoltane, labe teoprolol, tertatolol, terthianolol, tienoxolol, tilisolol. talol, landiolol, levobetaxolol, levobunolol, levocicloprolol, timolol, tiprenolol, tolamolol, toliprolol, tribendilol, trigev levomoprolol, medroxalol, mepindolol, metalol, metipra olol, Xibenolol, and Xipranolol. nolol, metoprolol, moprolol, nadolol, nadoxolol, nafetolol. 0088. In certain embodiments, the compounds disclosed nebivolol, neraminol, nifenalol, nipradillol, oberadillol, Oxpre herein can be combined with one or more angiotensin II nolol, pacrinolol, pafenolol, pamatolol, pargolol, parodilol. receptor antagonists, including, but not limited to, cande penbutolol, penirolol, PhOA-33, pindolol, pirepolol, prac Sartan, eprosartan, irbesartan, losartan, olmesartan, tasosar tolol, primidolol, procinolol, pronethalol, propafenone, pro tan, telmisartan, and Valsartan. pranolol, ridazolol, ronactolol, Soquinolol, Sotalol, spiren 0089. In certain embodiments, the compounds disclosed dolol, SR 59230A, sulfinalol, TA-2005, tallinolol, tazolol, herein can be combined with one or more angiotensin-con teoprolol, tertatolol, terthianolol, tienoxolol, tilisolol, Verting enzyme inhibitors, including, but not limited to, cap timolol, tiprenolol, tolamolol, toliprolol, tribendilol, trigev topril, enalapril, lisinopril, perindopril, ramipril, quinapril, olol, Xibenolol, and Xipranolol. benazepril, cilaZapril, fosinopril, trandolapril, spirapril, dela 0094. In certain embodiments, the compounds disclosed pril, moexipril, temocapril, Zofenopril, and imidapril. herein can be combined with one or more calcium channel 0090. In certain embodiments, the compounds disclosed blockers, including, but not limited to amlodipine, felodipine, herein can be combined with one or more anti-arrhythmics, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, including, but not limited to quinidine, procainamide, disopy nitrendipine, lacidipine, nilvadipine, manidipine, barnid ramide, Sparteine, ajmaline, prajmaline, lorajmine, lidocaine, ipine, lercanidipine, cilnidipine, benidipine, mibefradil, Vera mexiletine, tocainide, aprindine, propafenone, flecainide, pamil, gallopamil, diltiazem, fendiline, bepridil, lidoflazine, lorcainide, encainide, amiodarone, bretylium tosilate, bunaf and perhexiline. tine, dolfetilide, ibutilidem, tedisamil, moracizine, and ciben 0095. In certain embodiments, the compounds provided Zoline. herein can be combined with one or more fibrates, including, 0091. In certain embodiments, the compounds provided but not limited to, clofibrate, bezafibrate, aluminium clofi herein can be combined with one or more antithrombotics, brate, gemfibrozil, fenofibrate, simfibrate, ronifibrate, including, but not limited to, dicoumarol, phenindione, war ciprofibrate, etofibrate, and clofibride. farin, phenprocoumon, acenocoumarol, ethyl biscoumac 0096. In certain embodiments, the compounds disclosed etate, clorindione, diphenadione, tioclomarol, heparin, anti herein can be combined with one or more HMG-CoA reduc thrombin III, dalteparin, enoxaparin, nadroparin, parnaparin, tase inhibitors, including, but not limited to, atorvastatin, reviparin, danaparoid, tinzaparin, Sulodexide, bemiparin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, ditazole, cloricromen, picotamide, clopidogrel, ticlopidine, pravastatin, rosuvastatin, and simvastatin. acetylsalicylic acid, dipyridamole, carbasalate calcium, epo 0097. The compounds disclosed herein can also be admin prostenol, indobufen, iloprost, abciximab, aloxiprin, eptifi istered in combination with other classes of compounds, batide, tirofiban, triflusal, beraprost, treprostinil, prasugrel, including, but not limited to, decongestant treatments; anti streptokinase, alteplase, urokinase, fibrinolysin, brinase, tussive treatments; mucolytic treatments; expectorant treat reteplase, Saruplase, ancrod, drotrecogin alfa (activated), ments; antiallergic non-steroidal treatments; steroidal drugs; tenecteplase, protein C, desirudin, lepirudin, argatroban, antihistamine treatments; leukotriene receptor antagonists; melagatran, Ximelagatran, bivalirudin, dabigatran etexilate, phosphodiesterase inhibitors: CYP3A inhibitors: CYP3A defibrotide, dermatan Sulfate, fondaparinux, and rivaroXaban. inducers; protease inhibitors; antifugal agents; antibacterials; 0092. In certain embodiments, the compounds provided antimycobacterial agents; sepsis treatments; steroidal drugs; herein can be combined with one or more antiplatelet agents, non-steroidal anti-inflammatory agents, norepinephrine including, but not limited to, abciximab, eptifibatide, reuptake inhibitors (NRIs) such as atomoxetine; dopamine tirofiban, clopidogrel, praSugrel, ticlopidine, ticagrelor, bera reuptake inhibitors (DARIs), such as methylphenidate; sero prost, prostacyclin, iloprost, treprostinil, acetylsalicylic acid, tonin-norepinephrine reuptake inhibitors (SNRIs), such as aloxiprin, carbasalate calcium, indobufen, dipyridamole, milnacipran; sedatives, such as diazepham; norepinephrine picotamide, terutroban, cilostazol, dipyridamole, triflusal, dopamine reuptake inhibitor (NDRIs), such as bupropion; cloricromen, and ditazole. serotonin-norepinephrine-dopamine-reuptake-inhibitors 0093. In certain embodiments, the compounds disclosed (SNDRIs), such as Venlafaxine; monoamine oxidase inhibi herein can be combined with one or more beta-adrenergic tors, such as selegiline; hypothalamic phospholipids; endot antagonists, including, but not limited to, acebutolol. helin converting enzyme (ECE) inhibitors, such as phos adaprolol, adimolol, afurolol, alprenolol, alprenoXime, amo phoramidon; opioids, such as tramadol; thromboxane Sulalol, ancarolol, arnolol, arotinolol, atenolol, befunolol. receptor antagonists, such as ifetroban; potassium channel betaxolol, bevantolol, bisoprolol, bopindolol, bormetolol. openers; thrombin inhibitors, such as hirudin; hypothalamic bornaprolol, brefonalol, bucindolol, bucumolol, bufetolol. phospholipids; growth factor inhibitors, such as modulators buftiralol, bufuralol, bunitrolol, bunolol, bupranolol, buro of PDGF activity; platelet activating factor (PAF) antago crolol, butaxamine, butidrine, butofilolol, capsinolol, cara nists; Factor VIIa Inhibitors and Factor Xa Inhibitors; renin Zolol, carpindolol, carteolol, carvedilol, celiprolol, ceta inhibitors; neutral endopeptidase (NEP) inhibitors; vasopep molol, cicloprolol, cinamolol, cloranolol, cyanopindolol. sidase inhibitors (dual NEP-ACE inhibitors), such as omap dalbraminol, dexpropranolol, diacetolol, dichloroisoprena atrilat and gemopatrilat, squalene synthetase inhibitors; bile line, dihydroalprenolol, dilevalol, diprafenone, draquinolol. acid sequestrants, such as questran; niacin; anti-atheroscle dropranolol, ecastolol, epanolol, ericolol, ersentilide, rotic agents, such as ACAT inhibitors: MTP Inhibitors; potas esatenolol, esmolol, esprolol, eugenodilol, exaprolol, falin sium channel activators; alpha-muscarinic agents; beta-mus US 2016/01932 12 A1 Jul. 7, 2016 carinic agents, such as carvedilol and metoprolol; diuretics, Zine, mitotane, hexamethylmelamine, gold compounds, plati such as chlorothlazide, hydrochiorothiazide, flumethiazide, num coordination complexes, such as cisplatin, satraplatin, hydroflumethiazide, bendroflumethiazide, methylchlorothi and carboplatin. 0098. Thus, in another aspect, certain embodiments pro azide, trichioromethiazide, polythiazide, benzothlazide, vide methods for treating P2Y 12 receptor-mediated disorders ethacrynic acid, tricrynafen, chlorthalidone, furosenilde, in a human or animal Subject in need of such treatment com musolimine, bumetanide, triamterene, amiloride, and prising administering to said Subject an amount of a com spironolactone; anti-diabetic agents, such as biguanides (e.g. pound disclosed herein effective to reduce or prevent said metformin), glucosidase inhibitors (e.g., acarbose), insulins, disorder in the subject, in combination with at least one addi meglitinides (e.g., repaglinide), Sulfonylureas (e.g., glime tional agent for the treatment of said disorder that is known in the art. In a related aspect, certain embodiments provide piride, glyburide, and glipizide), thioZolidinediones (e.g. tro therapeutic compositions comprising at least one compound glitaZone, rosiglitaZone and pioglitaZone), and PPAR-gamma disclosed herein in combination with one or more additional agonists; mineralocorticoid receptor antagonists, such as agents for the treatment of P2Y 12 receptor-mediated disor spironolactone and eplerenone; growth hormone secreta ders. gogues; aP2 inhibitors; phosphodiesterase inhibitors, such as General Synthetic Methods for Preparing Compounds PDE III inhibitors (e.g., cilostazol) and PDE V inhibitors 0099 Isotopic hydrogen can be introduced into a com (e.g., sildenafil, tadalafil. Vardenafil); protein tyrosine kinase pound as disclosed herein by synthetic techniques that inhibitors; antiinflammatories; antiproliferatives, such as employ deuterated reagents, whereby incorporation rates are methotrexate, FK506 (tacrolimus, Prograf), mycophenolate pre-determined; and/or by exchange techniques, wherein mofetil: chemotherapeutic agents; immunosuppressants; incorporation rates are determined by equilibrium conditions, anticancer agents and cytotoxic agents (e.g., alkylating and may be highly variable depending on the reaction condi agents. Such as nitrogen mustards, alkyl Sulfonates, tions. Synthetic techniques, where tritium or deuterium is nitrosoureas, ethylenimines, and triaZenes); antimetabolites, directly and specifically inserted by tritiated or deuterated Such as folate antagonists, purine analogues, and pyrridine reagents of known isotopic content, may yield high tritium or analogues; antibiotics, such as anthracyclines, bleomycins, deuterium abundance, but can be limited by the chemistry mitomycin, dactinomycin, and plicamycin; enzymes, such as required. Exchange techniques, on the other hand, may yield lower tritium or deuterium incorporation, often with the iso L-asparaginase; farnesyl-protein transferase inhibitors; hor tope being distributed over many sites on the molecule. monal agents, such as glucocorticoids (e.g., cortisone), estro 0100. The compounds as disclosed herein can be prepared gens/antiestrogens, androgens/antiandrogens, progestins, by methods known to one of skill in the art and routine and luteinizing hormone-releasing hormone anatagonists, modifications thereof, and/or following procedures similar to and octreotide acetate; microtubule-disruptor agents, such as those described in the Example section herein and routine ecteinascidins; microtubule-stablizing agents. Such as paci modifications thereof, and/or procedures found in Shireman taxel, docetaxel, and epothilones A-F. plant-derived prod et al., Tetrahedron Letters 2000, 41,9537-9540, Bioorganic ucts, such as Vinca alkaloids, epipodophyllotoxins, and tax & Medicinal Chemistry Letters 2007, 17, 6013-6018; US anes; and topoisomerase inhibitors; prenyl-protein 2003.0148888 and WO 2010030224: WO 2000034283; WO 2001092262: WO 2001092263; WO 199905142, which are transferase inhibitors; and cyclosporins; steroids, such as hereby incorporated in their entirety, and references cited prednisone and dexamethasone; cytotoxic drugs, such as aza therein and routine modifications thereof. Compounds as dis thiprine and cyclophosphamide; TNF-alpha inhibitors, such closed herein can also be prepared as shown in any of the as tenidap; anti-TNF antibodies or soluble TNF receptor, such following schemes and routine modifications thereof. as etanercept, rapamycin, and leflunimide; and cyclooxyge 0101 The following schemes can be used to practice the nase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; present invention. Any position shown as hydrogen may and miscellaneous agents such as, hydroxyurea, procarba optionally be replaced with deuterium.

Scheme I OH

R3 R2 O R. R. R2 O R. R. R2 - 5-( O 4 -- \ -- F HO F C \ F R4 R4 R4 R F R F R F 1 2 3 US 2016/01932 12 A1 Jul. 7, 2016 11

-continued

US 2016/01932 12 A1 Jul. 7, 2016 12

-continued

C C NH Nsa N 2 15 n s R14 R15 Rio Ro R14 R15 Rio 2 N >S-X. N1,No. -- R13 S N C R12 R11 R12 R11 22 21

0102 Compound 1 is treated with malonic acid in the appropriate mixture of dimethyl Sulfoxide and water, to give presence of an appropriate base. Such as piperidine, in an compound 8. Compound 8 is reacted with an appropriate appropriate solvent, such as pyridine, to give compound 2. chlorinating agent, Such as thionyl chloride, in an appropriate Compound 2 is reacted with an appropriate chlorinating Solvent, such as toluene, to give an acyl cholide intermediate agent, Such as thionyl chloride, in the presence of an appro which is then reacted with an appropriate azide source. Such priate base. Such as pyridine, in an appropriate solvent, Such as sodium azide, in the presence of an appropriate base. Such as toluene, to give compound 3. Compound 3 is reacted with as Sodium carbonate, in the presence of an appropriate phase compound 4 in the presence of an appropriate base. Such as transfer catalyst, such as tetrabutylammonium bromide, to pyridine, in an appropriate solvent, Such as toluene, to give give compound 9. Compound 9 is reacted at an elevated compound 5. Compound 5 is reacted with compound 6, in the temperature in an appropriate solvent, such as toluene, to give presence of an appropriate base. Such as sodium hydroxide, in compound 10. Compound 11 is reacted with an appropriate an appropriate solvent, Such as an appropriate mixture of amine protecting reagent, such as benzyl chloroformate, in dimethyl Sulfoxide and water, to give compound 7. Com the presence of an appropriate base. Such as potassium car pound 7 is reacted with an appropriate hydroxide base. Such bonate, in an appropriate solvent, Such as 4-methyl-2-pen as sodium hydroxide, in an appropriate solvent, such as an tanone, to give compound 12. Compound 12 is reacted with US 2016/01932 12 A1 Jul. 7, 2016 13 compound 13 in the presence of an appropriate base. Such as Compound 24 is reacted with compound 10 in the presence of potassium tert-butoxide, in an appropriate solvent, such as an appropriate base, such as triethylamine, in an appropriate tetrahydrofuran, to give compound 14. Compound 14 is Solvent, such as acetonitrile, to give compound 25. Com treated with an appropriate reducing reagent, such as lithium pound 25 is treated with an appropriate ketal deprotecting borohydride, in an appropriate solvent, Such as tetrahydrofu reagent, such as hydrochloric acid, in an appropriate solvent, Such as a combination of water and methanol, to give a com ran, to give compound 15. Compound 15 is treated with an pound 26 of Formula I. appropriate deprotecting reagent, such as a combination of 0103 Deuterium can be incorporated to different posi hydrogen gas and palladium on carbon, in an appropriate tions synthetically, according to the synthetic procedures as Solvent. Such as ethanol, to give compound 16. Compound 17 shown in Scheme I, by using appropriate deuterated interme is reacted with compound 18 in the presence of an appropriate diates. For example, to introduce deuterium at one or more base, such as Sodium hydroxide, in an appropriate solvent, positions of R-Ra, compound 1 with the corresponding deu Such as an appropriate mixture of water and 1-methyl-2- terium substitutions can be used. To introduce deuterium at pyrrolidinone, to give compound 19. Compound 19 is reacted R7, malonic acid with the corresponding deuterium Substitu with an appropriate base, such as sodium hydroxide, and then tions can be used. To introduce deuterium at one or more reacted with an aromatic amine. Such as para-toluidine, in the positions of Rs-R compound 6 with the corresponding deu presence of an appropriate nitrite salt, such as Sodium nitrite, terium substitutions can be used. To introduce deuterium at in the presence of an appropriate acid. Such as hydrochloric one or more positions of Re-R, compound 11 with the acid, in an appropriate solvent, such as water, to give com corresponding deuterium Substitutions can be used. To intro pound 20. Compound 20 is reacted with an appropriate chlo duce deuterium at one or more positions of Ra-Rs, com rinating agent. Such as phosphorous oxychloride, in an appro pound 13 with the corresponding deuterium Substitutions can priate solvent, such as toluene, to give compound 21. be used. To introduce deuterium at one or more positions of Compound 21 is reacted with an appropriate reducing agent, Re-R-7, lithium borodeuteride can be used. To introduce Such as a hydrogen gas, in the presence of an appropriate deuterium at one or more positions of R-Rs, compound 18 catalyst, such as platinum on carbon, in an appropriate Sol with the corresponding deuterium Substitutions can be used. vent, such as 2-propanol, to give compound 22. Compound 22 0104 Deuterium can be incorporated to various positions is reacted with compound 16, in the presence of an appropri having an exchangeable proton, such as the amine N-H and ate base, such as triethylamine, in an appropriate solvent, hydroxyl O—Hs, via proton-deuterium equilibrium Such as ethanol, to give compound 23. Compound 23 is exchange. For example, to introduce deuterium at Rs. R reacted with an appropriate nitrite salt, such as sodium nitrite, R, and Rs. this proton may be replaced with deuterium in the presence of an appropriate acid, Such as acetic acid, in selectively or non-selectively through a proton-deuterium an appropriate solvent, such as water, to give compound 24. exchange method known in the art.

Scheme II

O

N H -- O l N O O H R21 R20 27 28 40

| R13's I 41

R18 R17 O O

AO R20 1n O O 1n N N R R13 R15 H I6 R21 O R14 29 42 US 2016/01932 12 A1 Jul. 7, 2016 14

-continued

O O 1No 1N R12 R15 R13 R14 43 |

US 2016/01932 12 A1 Jul. 7, 2016 15

-continued

R15 Rio Ro

R12 R11 18

OH N1 N

HS - N - OH 17

OH

R9 N

S - N - OH

19

OH NO N1 N 2

l N 2 OH

C NO R15 Ro Ro N n R14 l 2 R13 S N C

47

US 2016/01932 12 A1 Jul. 7, 2016 17

-continued

0105 Compound 27 is reacted with compound 28 in the in an appropriate solvent, such as methanol ord-methanol, to presence of an appropriate oxidant, Such as a combination of give compound 43. Compound 43 is reacted with an appro oxalyl chloride, dimethyl sulfoxide, and triethylamine, in an priate decarboxylating catalyst, such as Sodium chloride, in appropriate solvent, such as a combination of dichlo an appropriate solvent, such as a combination of water and romethane and dimethyl sulfoxide, to give compound 29. dimethylsulfoxide, to give compound 44. Compound 44 is Compound 29 is reacted with an appropriate oxidizing agent, treated with an appropriate reducing reagent, Such as lithium such as a combination of osmium tetroxide and N-methyl aluminum hydride, in an appropriate solvent, such as diethyl morpholine N-oxide, in an appropriate solvent, such as a ether, to give compound 45. Compound 45 is treated with an combination of water and tetrahydrofuran, to give compound appropriate iodinating reagent, such as hydroiodic acid, to 30. Compound 30 is reacted with an appropriate 1,2-dihy give compound 18. Compound 18 is reacted with compound droxy protecting group, such as 2.2-dimethoxypropane, in 17 in the presence of an appropriate base. Such as sodium the presence of an appropriate acid, Such as p-toluenesulfonic hydroxide, in an appropriate solvent, such as an appropriate acid, to give compound 31. Compound 31 is reacted with an mixture of water and 1-methyl-2-pyrrolidinone, to give com appropriate reducing agent, such as sodium borohydride, in pound 19. Compound 19 is reacted with an appropriate nitrat an appropriate solvent, Such as methanol, to give compound ing agent, Such as nitric acid, to give compound 46. Com 32. Compound 32 is treated with an appropriate reducing pound 46 is reacted with an appropriate chlorinating agent, agent, such as a combination of hydrogen gas and palladium Such as phosphorous oxychloride, in the presence of an on carbon, in an appropriate solvent, Such as methanol, to give appropriate base. Such as N,N-diethylbenzenamine, to give compound 33. Compound 33 is reacted with an appropriate compound 47. Compound 47 is reacted with compound 16 in amine protecting reagent, such as benzyl chloroformate, in an appropriate solvent, such as tetrahydrofuran, to give com the presence of an appropriate base, such as potassium car pound 48. Compound 48 is treated with an appropriate reduc bonate, in an appropriate solvent, such as a combination of ing reagent, such as a combination of iron and acetic acid, in water and tetrahydrofuran, to give compound 34. Compound an appropriate solvent. Such as a mixture of ethanol and water, 35 is treated with an appropriate reducing reagent, such as to give compound 23. Compound 23 is reacted with an appro lithium aluminum hydride, in an appropriate solvent, Such as priate nitrite salt, such as Sodium nitrite, in the presence of an tetrahydrofuran, to give compound 36. Compound 36 is appropriate acid. Such as acetic acid, in an appropriate Sol reacted with an appropriate alcohol protecting reagent. Such vent. Such as a combination of toluene and water, to give as benzyl bromide, in the presence of an appropriate base, compound 24. Compound 2 is reacted with an appropriate Such as silver oxide, in an appropriate solvent, such as dichlo chlorinating agent, Such as oxalyl chloride, in the presence of romethane, to give compound 37. Compound 37 is reacted an appropriate catalyst, such as dimethylformamide, in an with an appropriate brominating agent, such as a combination appropriate solvent, such as dichloromethane, to give com of N-bromosuccinimide and triphenylphosphine, in an appro pound 3. Compound 3 is reacted with an appropriate chiral priate solvent, Such as tetrahydrofuran, to give compound 38. auxiliary, Such as (2R)-bornane-10.2-Sultam, in the presence Compound 34 is reacted with compound 38 in the presence of of an appropriate base. Such as triethylamine, in an appropri an appropriate base, such as Sodium hydride, in an appropri ate solvent, Such as dichloromethane, to give compound 49. ate solvent. Such as dimethylformamide, to give compound Compound 49 is reacted with compound 50, in the presence 39. Compound 39 is treated with an appropriate deprotecting ofan appropriate catalyst, Such as palladium (II) acetate, in an reagent, such as a combination of hydrogen gas and palla appropriate solvent. Such as an appropriate mixture of diethyl dium on carbon, in an appropriate solvent, Such as methanol, ether and dichloromethane, to give compound 51. Compound to give compound 16. Compound 40 is reacted with com 51 is reacted with an appropriate base. Such as lithium pound 41 in the presence of an appropriate base. Such as hydroxide, in an appropriate solvent, such as an appropriate Sodium ethoxide, in an appropriate solvent, such as ethanol, mixture of tetrahydrofuran and water, to give compound 8. to give compound 42. Compound 42 is reacted with an appro Compound 8 is reacted with an appropriate acyl azide-form priate base, such as triethylamine, at an elevated temperature, ing reagent, Such as diphenylphosphoryl azide, in the pres US 2016/01932 12 A1 Jul. 7, 2016 ence of an appropriate base, such as triethylamine, at elevated Step 1 temperature, in an appropriate solvent, Such as toluene, to give compound 10. Compound 24 is reacted with compound 0110 10 in the presence of an appropriate base, such as diisopro pylethylamine, in an appropriate solvent. Such as dichlo romethane, to give compound 25. Compound 25 is treated O with an appropriateketal deprotecting reagent, such as hydro > ul OH + NHOHHCI -> chloric acid, in an appropriate solvent. Such as a combination of water and methanol, to give a compound 26 of Formula I. O 0106 Deuterium can be incorporated to different posi OH tions synthetically, according to the synthetic procedures as shown in Scheme I, by using appropriate deuterated interme diates. For example, to introduce deuterium at one or more positions of Re-R, compound 28 with the corresponding O deuterium substitutions can be used. To introduce deuterium at R-Rs, compound 41 with the corresponding deuterium Substitutions can be used. To introduce deuterium at R, (R)-tert-Butyl 1-(hydroxyamino)-1-oxopropan-2- deuterium oxide and/or de-deuterium oxide can be used. To ylcarbamate introduce deuterium at R, da-methanol can be used. To 0111. At about 0°C., isopropyl chloroformate (86.05 g, introduce deuterium at one or more positions of R-Ro or 702.16 mmol. 1.00 equiv.) was added dropwise, over a period R-R-7, lithium aluminum deuteride can be used. To intro of 60 minutes, to a stirred mixture of (S)-2-(tert-butoxycar duce deuterium at one or more positions of R-R and R. bonylamino)propanoic acid (118 g. 623.65 mmol. 1.00 compound 2 with the corresponding deuterium Substitutions equiv.), tetrahydrofuran (500 mL), and triethylamine (63.63 can be used. To introduce deuterium at one or more positions g, 628.82 mmol. 1.00 equiv.). The resulting mixture was then of Rs-R compound 50 with the corresponding deuterium stirred at about 0°C. for about 2 hours, and then the solids Substitutions can be used. were removed by filtration. The resulting filtrate was then 0107 Deuterium can be incorporated to various positions added to a hydroxylamine solution (formed by first stirring a having an exchangeable proton, such as the amine N-H and mixture of sodium hydroxide (37.6 g., 940.00 mmol. 1.50 hydroxyl O—Hs, via proton-deuterium equilibrium equiv.), methanol (500 mL), and hydroxylamine hydrochlo exchange. For example, to introduce deuterium at Rs. R ride (65g,935.39 mmol, 1.50 equiv) at about 0°C. for about R, and Rs. this proton may be replaced with deuterium 2 hours, and then removing the resulting solids by filtration). selectively or non-selectively through a proton-deuterium The resulting mixture was stirred at about 0°C. for about 2 exchange method known in the art. hours, the solids were removed by filtration, and the resulting filtrate was concentrated in vacuo. The resulting residue was 0108. The invention is further illustrated by the following purified by silica gel column chromatography (ethyl acetate/ examples. All IUPAC names were generated using Cam petroleum ether (1:1)) to give the title product as a white solid bridgeSoft's ChemDraw 10.0. (70 g; yield=55%). "H NMR (300 MHz, CDC1) 8: 5.18 (b. 1H), 4.21 (m, 1H), 2.06 (s, 1H), 1.46 (s, 9H), 1.40 (d. J=7.2 EXAMPLE1 Hz, 3H). (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-difluorophenyl) Step 2 cyclopropylamino)-5-(propylthio)-3H-1.2.3 triazolo O112 4,5-dipyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclo pentane-1,2-diol (ticagrelor) O E pi 0109 > ul : NH -- O H 1 O

O E

> ls : N O grH O

tert-Butyl-(R)-1-(3-oxa-2-aza-bicyclo[2.2.1]hept-5- en-2-yl)-1-oxopropan-2-ylcarbamate 0113. At about -78°C. and under an atmosphere of nitro gen, oxalyl dichloride (30.43 g, 239.74 mmol. 4.00 equiv.) was added dropwise, over a period of 20 minutes, to stirred US 2016/01932 12 A1 Jul. 7, 2016 solution of dimethylsulfoxide (28.1 g, 359.66 mmol. 6.00 Step 4 equiv.) in dichloromethane (200 mL). To this mixture was added dropwise, over a period of about 10 minutes, a solution 0116 of (R)-tert-butyl 1-(hydroxyamino)-1-oxopropan-2-ylcar bamate (12.24g, 59.94 mmol. 1.00 equiv.) and cyclopenta-1, 3-diene (4.15 g, 62.78 mmol. 1.05 equiv.) in a mixture of OH dichloromethane/dimethylsulfoxide (5:1) (60 mL). The O O resulting mixture was stirred for at about -78°C. for about 30 N minutes, and then triethylamine (66.8 mL) was added. The DJ’" resulting mixture was washed with 1M hydrochloric acid O H 1 (2x200 mL), and extracted with dichloromethane (3x100 O mL). After the organic layers were combined, the organic phase was washed with 10% sodium bicarbonate (2x200 NX -e- mL), dried over anhydrous sodium Sulfate, and concentrated O in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (1:10)) to give the desired product as a white solid (8.6 g; O yield=53%). "H NMR (300 MHz, CDC1) 8: 6.54 (s, 1H), 6.39 (m, 1H), 5.22-5.34 (m, 3H), 4.51 (m, 1H), 2.02 (d. J–8.4 >s- O HZ, 1H), 1.86 (d. J=8.7 Hz, 1H), 1.43 (s, 9H), 1.09 (m, 3H). Step 3 (2-(4,4-Dimethyl-3,5,8-trioxa-9-aza-tricyclo[5.2.1. 0°ldec-9-yl)-1-methyl-2-oxo-ethyl-carbamic acid 0114 tert-butyl ester 0117. A solution of tert-butyl (R)-1-(5,6-dihydroxy-3- oxa-2-aza-bicyclo[2.2.1]heptan-2-yl)-1-oxopropan-2-ylcar bamate (30.1 g, 99.56 mmol. 1.00 equiv.) in 2,2-dimethox ypropane (600 mL) and p-toluenesulfonic acid (1.1 g, 6.39 mmol, 0.06 equiv.) was stirred at about 22°C. for about 50 minutes. After adding a saturated Solution of sodium bicar >s--- bonate (450 mL), the mixture was extracted with ethylacetate (3x300 mL). The organic layers were combined and concen trated in vacuo to give the title product as a white solid (33.5 g; yield=98%). "H NMR (300 MHz, CDC1) 8: 5.22 (b. 1H), 4.89 (s, 1H), 4.70 (s, 1H), 4.61 (b. 1H), 4.33 (s. 2H), 2.24 (d. J=11.4 Hz, 1H), 1.82 (m, 1H), 1.52 (s.3H), 1.46 (s.9H), 1.32 OH (d. J=6.9 Hz, 3H), 1.27 (s.3H). Step 5 >u-l." 0118

tert-Butyl (R)-1-(5,6-dihydroxy-3-oxa-2-aza-bicyclo 2.2.1]heptan-2-yl)-1-oxopropan-2-ylcarbamate 0115. A solution of tert-butyl-(R)-1-(3-oxa-2-aza-bicyclo sur- -e- 2.2.1]hept-5-en-2-yl)-1-oxopropan-2-ylcarbamate (27.3 g, O 101.75 mmol. 1.00 equiv.) in teterahydrofuran: water (5:1) (600 mL), osmium tetroxide (230 mg 0.90 mmol, 0.01 equiv.), and N-methylmorpholine-N-oxide (25.26g, 215.62 Sl mmol. 2.10 equiv.) was stirred at about 20° C. for about 50 minutes. After adding sodium thiolsulfate (22g), the resulting solution was extracted with ethyl acetate (3x200 mL) and the organic layers combined. The organic phase was washed with 4,4-Dimethyl-3,5,8-trioxa-9-aza-tricyclo[5.2.1.0° a saturated sodium bicarbonate solution (1x250 mL) and then decane concentrated in vacuo to give the desired product as a yellow 0119) A mixture of 2-(4,4-dimethyl-3,5,8-trioxa-9-aza liquid (30.1 g; yield=98%). "H NMR (300 MHz, CDC1) 8: tricyclo[5.2.1.0° dec-9-yl)-1-methyl-2-oxo-ethyl-car 5.29 (b. 1H), 4.36-4.74 (m, 3H), 3.76-4.09 (m, 4H), 2.67 (m, bamic acid tert-butyl ester (33.5g, 97.84 mmol. 1.00 equiv.). 1H), 1.90 (m, 1H), 1.43 (s, 9H), 1.30 (d. J=6.9 Hz, 3H). methanol (500 mL), and sodium borohydride (14.67 g. 388. US 2016/01932 12 A1 Jul. 7, 2016 20

10 mmol. 4.00 equiv) was stirred at about 20°C. for about 50 4S,6R,6aS)-6-amino-2,2-dimethyl-tetrahydro-3aH-cyclo minutes. The pH value of the mixture was then adjusted to 3 pentad 1.3dioxol-4-ol (17.0 g, 98.15 mmol. 1.00 equiv.) by adding 1M hydrochloric acid. After extracting the mixture and sodium carbonate (20.8 g. 196.24 mmol. 2.00 equiv) in with ethyl acetate (200 mL), the aqueous layers were com tetrahydrofuran: water (5:1) (600 mL). Standard extractive bined and the pH was adjusted to 10 by adding a 10% sodium workup with ethyl acetate (3x200 mL) gave the title product bicarbonate solution. Standard extractive workup with ethyl as a white solid (20.5 g; yield=68%). "H NMR (300 MHz, acetate (3x300 mL) gave the title product as a white solid CDC1) 8: 7.30-7.39 (m, 5H), 5.20 (s. 2H), 4.60 (d. J=5.4 Hz, (16.7 g; yield=99.8%). "H NMR (300 MHz, CDC1) 8: 4.80 1H), 4.50 (d. J=5.4 Hz, 1H), 4.27 (s, 1H), 4.19 (d. J=5.7 Hz (b. 1H), 4.69 (s, 1H), 4.29 (d. J=5.4 Hz, 1H), 4.22 (d. J=5.4 1H), 2.26 (m, 1H), 1.71 (d. J=14.4 Hz, 1H), 1.47 (s.3H), 1.28 HZ, 1H), 3.77 (s, 1H), 2.28 (d. J=11.1 Hz, 1H), 1.65 (d. J=11.4 (s, 3H). HZ, 1H), 1.50 (s.3H), 1.27 (s.3H). Step 6 Step 8 0120 0.124

HO NH2 O

HN O O D{ He n HO O O HN --

(3aR.4S,6R,6aS)-6-amino-2,2-dimethyl-tetrahydro O 3al-cyclopentad 1.3dioxol-4-ol 0121 Under a pressurized hydrogen atmosphere (3 atm), a Br O - / suspension of 4,4-dimethyl-3,5,8-trioxa-9-aza-tricyclo5.2. 1.0° decane (16.7 g, 97.55 mmol, 1.00 equiv.), 10% palla dium on carbon (1.67 g), and methanol (250 mL) was stirred at about 20° C. for about 60 minutes. After filtering the Solution, the resulting filtrate was concentrated in vacuo to give the title product as a white solid (16.8 g; yield=99%). MS: m/z =174 (MH)". Step 7 0122)

HO NH, R Ethyl 2-((3aR.4S,6R,6aS)-6-(benzyloxycarbonyl)-2, n-y- 2-dimethyl-tetrahydro-3aH-cyclopentad 1.3di e -- C Her oXol-4-yloxy)acetate 0.125 Benzyl (3 aS.4R,6S,6aR)-6-hydroxy-2,2-dimethyl 'X' tetrahydro-3aFI-cyclopentad 1.3dioxol-4-ylcarbamate O (12.29 g, 39.99 mmol. 1.00 equiv.) was added to a solution of sodium hydride (70%) (1.44 g. 60.00 mmol. 1.05 equiv.) in HN dimethylformamide (200 mL). The solution was stirred at about -30° C. for about 30 minutes, and then ethyl 2-bro moacetate (7.68 g. 45.99 mmol. 1.20 equiv) was added. The resulting Solution was stirred at ambient temperature for st ro about 5.5 hours, and then water was added (500 mL). Follow ing standard extractive workup with ethyl acetate (3x200 mL), the resulting residue was purified by Silica gel column chromatography (ethyl acetate: petroleum ether (1:10)) to afford the title product as a colorless solid (0.9 g; yield=69%). "H NMR (300 MHz, CDOD) 8: 7.30-7.35 (m, 5H), 5.07 (s, Benzyl (3aS.4R,6S,6aR)-6-hydroxy-2,2-dimethyl 2H), 4.60 (d. J=5.7 Hz, 1H), 4.51 (d. J=5.7 Hz, 1H), 4.12-4.29 tetrahydro-3aH-cyclopentad 1.3dioxol-4-ylcar (q, J–16.5 Hz, 2H), 4.10-4.22 (q, J–7.2 Hz, 2H), 4.00 (d. bamate J=5.7 Hz, 1H), 3.92 (J-4.3 Hz, 1H), 2.17-2.19 (m, 1H), 1.84 0123. At about 0°C., benzyl carbonochloridate (18.4g, (d. J=14.7 Hz, 1H), 1.38 (s, 3H), 1.26 (s, 3H), 1.11-1.22 (t, 107.86 mmol. 1.05 equiv.) was added to the solution of (3aR, J=7.2 Hz, 3H). US 2016/01932 12 A1 Jul. 7, 2016 21

Step 9 -continued 0126 s O v

2-((3 aR.4S,6R,6aS)-6-amino-2,2-dimethyl-tetrahy dro-3 aH-cyclopentad 1.3dioxol-4-yloxy)ethanol I0129. A solution of ethyl 2-((3aR.4S,6R,6aS)-6-amino-2, 2-dimethyl-tetrahydro-3aH-cyclopentad 1.3dioxol-4- yloxy)acetate (4.2g, 16.2 mmol. 1.00 equiv.) in dry tetrahy drofuran (50 mL) was slowly added to a suspension of lithium aluminum hydride (1.23g, 32.4 mmol. 2.00 equiv.) in tetrahy drofuran (50 mL). The mixture was heated at reflux for about 1 hour, and then water was added (2 mL). After the solids were collected by filtration, the solids were washed with tetrahydrofuran (50 mL) and then dried in vacuo to give the title product as a yellow oil (2.3 g. 65%). MS: m/z 218 (MH)". Ethyl 2-((3aR.4S,6R,6aS)-6-amino-2,2-dimethyl Step 11 tetrahydro-3aFI-cyclopentad 1.3dioxol-4-yloxy) acetate O130 0127. Under an atmosphere of hydrogen, a suspension of ethyl 2-((3aR.4S,6R,6aS)-6-(benzyloxycarbonyl)-2,2-dim HO N OH ethyl-tetrahydro-3aH-cyclopentad 1.3dioxol-4-yloxy)ac + 1-N-1 —- etate (150 mg 0.38 mmol. 30.00 equiv.) and 10% palladium on carbon (16 mg, 0.15 mmol. 1.00 equiv) in methanol (10 N. mL) was stirred at ambient temperature for about 80 minutes. SH After filtering, the resulting filtrate was concentrated in vacuo HO OH to give the title product as a yellow solid (80 mg; yield=82%). "H NMR (300 MHz, CDC1,) 8: 4.64 (s, 1H), 4.42 (s, 1H), NS 4.08-4.20 (m, 4H), 3.87 (s, 1H), 3.31 (s, 1H), 2.17 (m. 1H), N 1.76 (m, 1H), 1.36 (s, 3H), 1.21-1.29 (m, 6H). S Step 10 0128

2-(Propylthio)pyrimidine-4,6-diol I0131) A solution of 2-mercaptopyrimidine-4,6-diol (25 g, 173.61 mmol. 1.00 equiv.), sodium hydroxide (15.8 g. 395.00 mmol. 2.27 equiv.), 1-methylpyrrolidin-3-one (50 mL), and 1-iodopropane (30.6 g. 180.00 mmol. 1.05 equiv.) dissolved in water (60 mL) was stirred at ambient temperature for about 48 hours. The pH value of the solution was adjusted to 2-3 by adding hydrochloric acid. The solids were then collected by filtration to give the product as an off-white solid (35 g; (crude)). "H NMR (300 MHz, DMSO-d) 8: 11.78 (b. 1H), 10.30 (b. 1H), 5.13 (s, 1H), 3.07 (t, J=7.2 Hz, 2H), 1.58-170 (m. 2H), 0.96 (t, J–7.2 Hz, 2H). US 2016/01932 12 A1 Jul. 7, 2016 22

Step 12 Step 14 (0132 0.136 "N."N + HNO (60%) -> "N." - S l l NO HO N OH l X HO ON 21 N

S l l -----

5-Nitro-2-(propylthio)pyrimidine-4,6-diol 0133) A solution of 2-(propylthio)pyrimidine-4,6-diol (3 g, 16.11 mmol. 1.00 equiv.) in nitric acid (65%) (10 mL) was stirred at ambient temperature for about 2 hours. After adding 2-((3aR.4S,6R,6aS)-6-(6-Chloro-5-nitro-2-(propy water (10 mL), the mixture was stirred at about 0°C. for about lthio)pyrimidin-4-ylamino)-2,2-dimethyl-tetrahydro 30 minutes. The resulting solids were collected by filtration to 3aFH-cyclopentad 1.3dioxol-4-yloxy)ethanol afford the title product as a yellow solid (1.8 g; yield=48%). H NMR (300 MHz, DMSO-d) 8: 3.17 (t, J=7.2 Hz, 2H), 0.137 A solution of 4,6-dichloro-5-nitro-2-(propylthio) 1.62-1.75 (m, 2H), 0.95-1.02, (t, J–7.2 Hz, 3H). pyrimidine (1.07 g., 3.99 mmol. 1.00 equiv.), and 2-((3aR.4S, 6R,6aS)-6-amino-2,2-dimethyl-tetrahydro-3ah-cyclopenta Step 13 d1.3dioxol-4-yloxy)ethanol (570 mg, 4.41 mmol. 1.20 equiv.) in tetrahydrofuran (20 mL) was stirred at 0-10°C. for 0134) about 2 hours and then water (20 mL) was added. Standard extractive workup with ethyl acetate (3x20 mL) afforded the title product as a yellow oil (800 mg; yield=45%). "H NMR NO NO (300 MHz, CDC1) 8: 8.65 (b. 1H), 4.66-4.76 (m, 2H), 4.56 HO OH C C (m. 1H), 3.99 (d. J–7.5 Hz, 1H), 3.70-3.87(m,3H), 3.64-3.67 N N (m. 1H), 3.07-3.20 (m, 2H), 2.34 (m. 1H), 1.97 (m. 1H), 1.76-1.82 (m, 2H), 1.46 (s, 3H), 1.27 (s, 3H), 1.07 (t, J–7.5 N2 N Hz, 3H). Step 15 0.138

4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine 0135 A solution of 5-nitro-2-(propylthio)pyrimidine-4,6- diol (1.8 g. 6.71 mmol. 1.00 equiv.), phosphoryl chloride (15 mL) and N,N-diethylbenzenamine (2 mL) was stirred at reflux for about 3 hours in an oil bath. After cooling the mixture to about 20°C. with a waterfice bath, the mixture was concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (1:100)) to give the title product as a yellow oil (1.1 g; yield=61%). H NMR (300 MHz, CDC1) 8: 3.15 (t, J=7.2 Hz, 2H), 1.73-1.87 (n,2H), 1.07-1.13 (J–7.2 Hz, 3H). US 2016/01932 12 A1 Jul. 7, 2016 23

-continued 2-((3aR.4S,6R,6aS)-6-(5-amino-6-chloro-2-(propylthio)py rimidin-4-ylamino)-2,2-dimethyl-tetrahydro-3aFI-cyclo pentad 1.3dioxol-4-yloxy)ethanol (800 mg, 1.91 mmol. 1.00 equiv.) and acetic acid (680 mg, 11.33 mmol. 5.90 equiv.) intoluene (9 mL). The resulting solution was stirred at about 20° C. for about 30 minutes, and then the pH value of the Solution was adjusted to 8-9 by adding potassium carbon ate. Following standard extractive workup with ethyl acetate (3x10 mL), the resulting residue was purified by silica gel column (ethyl acetate/petroleum ether (1:10)) to give the title product as a yellow oil (370 mg; yield=45%). "H NMR (300 MHz, CDC1) 8: 5.54-5.56 (q, J=2.4 Hz, J-6.3 Hz, 1H), 5.21-5.25 (m, 1H), 4.90 (d. J=6.3 Hz, 1H), 405-4.09 (m, 1H), 2-((3aR.4S,6R,6aS)-6-(5-Amino-6-chloro-2-(propy 3.50-3.66 (m, 4H), 3.23 (t, J–7.5 Hz, 2H), 2.68-2.72 (m, 1H), lthio)pyrimidin-4-ylamino)-2,2-dimethyl-tetrahydro 2.58 (m, 1H), 1.81-1.89 (m, 2H), 1.57 (s, 3H), 1.39 (s.3H), 3al-cyclopentad 1.3dioxol-4-yloxy)ethanol 1.12, (t, J–7.5 Hz, 3H). 0.139. A suspension of 2-((3aR,4S,6R,6aS)-6-(6-chloro 5-nitro-2-(propylthio)pyrimidin-4-ylamino)-2,2-dimethyl Step 17 tetrahydro-3aFI-cyclopentad 1.3dioxol-4-yloxy)ethanol (800 mg, 1.78 mmol. 1.00 equiv.), iron powder (800 mg. 0142 14.29 mmol, 8.00 equiv.), acetic acid (860 mg, 14.33 mmol. 8.00 equiv.) and water/ethanol (10 mL) was stirred at about 60° C. for about 20 minutes in an oil bath. After the solids O were removed by filtration, the resulting filtrate was extracted F O with dichloromethane (3x10 mL). The organic layers were HO 21 combined, dried over anhydrous Sodium sulfate, and concen -- C -e- trated in vacuo to give the title product as a yellow oil (780 C mg; yield=93%). MS: m/z. 419 (MH)". F O Step 16 O 0140 F C 21 C F HO HN 21

3-(3,4-Difluoro-phenyl)-acryloyl chloride 0143. At 0-5°C., oxalyldichloride (25.7g, 202.36 mmol, 3.00 equiv.) was added to a mixture of (E)-3-(3,4-difluo rophenyl)acrylic acid (12.4g, 67.38 mmol. 1.00 equiv.), N.N- dimethylformamide (1 mL), and dichloromethane (150 mL). The solution was stirred at ambient temperature for about 2 hours, and then concentrated in vacuo to give the title product, which was used in the next step without any further purifica tion.

Step 17 0144)

O 2-((3aR.4S,6R,6aS)-6-(7-Chloro-5-(propylthio)-3H 1.2.3 triazolo 4,5-dipyrimidin-3-yl)-2,2-dimethyl C 21 F tetrahydro-3aFI-cyclopentad 1.3dioxol-4-yloxy) -- NH -e- ethanol 0141. A solution of sodium nitrite (148 mg, 2.14 mmol. F /7, \, 1.12 equiv.) in water (1 mL) was added to a solution of US 2016/01932 12 A1 Jul. 7, 2016 24

-continued (48.2 g, 126.51 mmol. 1.00 equiv.), palladium(II) acetate (200 mg, 1.04 mmol) in dichloromethane (300 mL) was then added to the mixture. The mixture was stirred at ambient temperature for about 1 hour, acetic acid (100 mL) was added, O and then water (500 mL) was added. Standard extractive workup with dichloromethane (2x100 mL) afforded the title F product as a light-yellow oil (48 g; yield=80%). "H NMR 1N 21 (300 MHz, CDC1) 8: 6.97-7.09 (m, 3H), 3.91-3.95 (m. 1H), 3.44-3.57 (q, J=13.8 Hz, J-24.9 Hz), 2.56 (m. 2H), 2.15 (m, F 2H), 1.90-1.95 (m, 3H), 1.76-1.82 (m, 1H), 1.22-1.47 (m, 3H), 1.20 (s.3H), 1.00 (s.3H). 3aS-1 (E).3a,6,7a-1-3-(3,4-Difluorophenyl)-1- Step 19 oxo-2-propenyl-hexahydro-8,8-dimethyl-3H-3a,6- methano-2,1-benzisothiazole-2,2-dioxide 0149 0145 At 0-5°C., a solution of 3-(3,4-difluoro-phenyl)- acryloyl chloride in dichloromethane (30 mL) was added to a mixture of (2R)-bornane-10.2-sultam (14.5 g. 67.35 mmol. 1.00 equiv), triethylamine (20.4g, 201.98 mmol. 3.00 equiv), and dichloromethane (120 mL). The resulting solution was stirred at ambient temperature for about 3 hours and then water (40 mL) was added. Standard extractive workup with dichloromethane (2x40 mL) gave the title product as an off white solid (18.5 g; yield=72%). Kr F Hip 0146 H NMR (300 MHz, CDC1) 8: 7.68 (d. J=15.6 Hz, / \, O 1H), 7.15-7.45 (m, 3H), 7.19 (d. J=15.6 Hz, 1H), 4.00 (m, F 1H), 3.55 (q, J=13.8 Hz, J-240 Hz), 2.18 (m, 2H), 1.93 (m, 2H), 1.37-1.48 (m, 2H), 1.22 (s.3H), 0.96 (s.3H). s W F Step 18 O F 0147

(1R,2R)-2-(3,4-Difluorophenyl)cyclopropanecar boxylic acid O 0150. A mixture of 3aS-1 (1R,2R).3a,6,7a-1-2-(3,4- difluorophenyl)cyclopropylcarbonyl-hexahydro-8,8-dim F ethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide (48 g, 121.52 mmol. 1.00 equiv.) in 10% lithium hydroxide (200 /\,7, - C F mL) and tetrahydrofuran (200 mL) was stirred at about 50° C. for about 0.5 hours. The mixture was cooled to ambient temperature, and washed ether (2x100 mL). The pH value of the aqueous layer was adjusted to 3 by adding 12N hydro chloric acid. Following standard extractive workup with ether (3x200 mL), the crude residue was purified by silica gel N 8 F column chromatography (ethyl acetate/petroleum ether s1 w (1:4)) to give the title product as a white solid (16.0 g; yield=66%). "H NMR (300 MHz, CDC1) 8: 705-7.14 (m, / \, 1H), 6.85-6.96 (m, 2H), 2.54-2.60 (m. 1H), 1.84-1.90 (m, F 1H), 1.65-1.72 (m, 1H), 1.30-1.40 (m. 1H).

3aS-1 (1R,2R).3a,6,7a-1-2-(3,4-Difluorophe Step 20 nyl)cyclopropylcarbonyl-hexahydro-8,8-dimethyl 0151 3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide 0148. At 0-5°C., 1-methyl-1-nitrosourea (39.1 g, 379.61 mmol. 2.50 equiv.) was added in portions to a mixture of 50% HO s F aqueous sodium hydroxide (150 mL) and ethyl ether (300 w mL). After the Solid was dissolved, the aqueous phase was -e- removed. At 0-5°C., a solution of 3aS-1 (E).3a,6,7a-1-3- O (3,4-difluorophenyl)-1-oxo-2-propenyl-hexahydro-8.8- F dimethyl-3H-3a,6-methano-2,1-benzisothiazole-2,2-dioxide US 2016/01932 12 A1 Jul. 7, 2016

-continued 2-((3aR.4S,6R,6aS)-6-(7-((1R,2S)-2-(3,4-Difluo rophenyl)cyclopropylamino)-5-(propylthio)-3H-1.2. 3triazolo 4,5-dipyrimidin-3-yl)-2,2-dimethyl-tet HNY rahydro-3aFH-cyclopentad 1.3dioxol-4-yloxy) ethanol 0154) A solution of 2-((3aR.4S,6R,6aS)-6-(7-chloro-5- (propylthio)-3H-1.2.3 triazolo 4,5-dipyrimidin-3-yl)-2.2- dimethyl-tetrahydro-3aH-cyclopentad 1.3dioxol-4- yloxy)ethanol (370 mg. 0.86 mmol. 1.00 equiv) (15 mL), (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine (145.6 mg, 0.86 mmol. 1.00 equiv.) and N,N-diisopropylethylamine 0152. A solution of (1R,2R)-2-(3,4-difluorophenyl)cyclo (155.7 mg, 1.21 mmol. 1.20 equiv.) in dichloromethane was propanecarboxylic acid (8.0 g, 40.40 mmol. 1.00 equiv.). stirred at ambient temperature for about 16 hours, and then diphenylphosphoryl azide (11.2g, 40.73 mmol. 1.00 equiv.). water (10 mL) was added. Standard extractive workup with triethylamine (6.2g, 61.39 mmol. 1.50 equiv.) in toluene (60 dichloromethane (3x10 mL) gave the title product as a yellow mL) was heated at reflux for about 1 hour and then refluxing oil (450 mg. yield=93%), m/z 563 (MH)". 6N hydrogen chloride was added. The mixture was kept at reflux for 16 hours, and then cooled to ambient temperature. Step 22 The resulting mixture was concentrated in vacuo, and the resulting residue was dissolved in water/ether (1:1) 200 mL). O155 Following standard extractive workup with ether (3x100 mL), the resulting residue was purified by Silica gel column chromatography (ethyl acetate/petroleum ether (1:4~ 1:0)) to give the title product as a light-brown Solid (6.2 g; yield=91%). "H NMR (300 MHz, CDC1) 8: 6.98-7.07 (m, HNW F 1H), 6.72-6.81 (m, 2H), 2.40 (m, 1H), 1.82-1.87 (n, 1H), 1.05-1.11 (m, 1H), 0.85-0.96 (m. 1H). N1 N-NN F 2 y Step 21 N-1Ns N N

0153 ... II IO

to \ Oy \,-\O HN w F -- HNW F

F C N F HO

(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-difluorophenyl) cyclopropylamino)-5-(propylthio)-3H-1.2.3 triazolo 4,5-dipyrimidin-3-yl)-5-(2-hydroxyethoxy) cyclo pentane-1,2-diol (ticagrelor-do) 0156. A solution of 2-((3aR,4S,6R,6aS)-6-(7-((1R,2S)-2- (3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3H 1.2.3 triazolo 4,5-dipyrimidin-3-yl)-2,2-dimethyl-tetrahy dro-3aH-cyclopentad 1.3dioxol-4-yloxy)ethanol (450 mg. 0.80 mmol. 1.00 equiv.) in methanol (4 mL) and 12N hydro chloric acid (1.5 mL) was stirred at ambient temperature for about 3 hours. The pH value of the solution was adjusted to 8-9 by adding potassium carbonate. Following standard extractive workup with ethyl acetate (3x20 mL), the resulting crude residue was purified by silica gel column chromatog US 2016/01932 12 A1 Jul. 7, 2016 26 raphy (dichloromethane/methanol (50: 1)) to give a semi Step 2 crude product (200 mg; yield=48%). The semi-crude product, which contained about 5% of other diastereoisomers, was (0160 then further purified by chiral-prep HPLC (column: Chiral pak IA2x25 cm, 5 um Chiral-P(IA)004IAO0CJ-MB003) to afford the title compound (100 mg). CI'' -43.2° (c. 0.2 D D Br g/100 mL in MeOH). LC-MS: m/z =523.0 (MH)", Retention OH time: 1.58 minute. "H NMR (300 MHz, CDOD) 8: 7.08-7.23 HO (m,3H), 5.13 (q, 1H), 4.75-4.79 (m, 1H), 4.17-4.20 (m. 1H), D D 3.91-3.95 (m. 1H), 3.63-3.73 (m, 4H), 3.06–3.26 (m, 2H), 2.90-3.00 (m. 1H), 2.70-2.80 (m, 1H), 2.05-2.29 (m, 2H), 1.60- 1.88 (m, 2H), 1.38-1.59 (m, 2H), 0.94 (t, J–7.5 Hz, 3H). D D HO EXAMPLE 2 O (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-difluorophenyl) D D cyclopropylamino)-5-(propylthio)-3H-1.2.3 triazolo 4.5-dpyrimidin-3-yl)-5-(2-hydroxy-da-ethoxy)cy clopentane-1,2-diol (ticagrelor-d) 2-(Benzyloxy)-di-ethanol O157 0.161 Silver oxide (11.05 g, 47.72 mmol. 1.50 equiv.), and benzylbromide (5.98 g., 34.99 mmol. 1.10 equiv.) were added to a stirred solution of dai-ethane-1,2-diol (2.1 g, 31.81 mmol. Y F 1.00 equiv.) in dichloromethane (40 mL). The mixture was HN' stirred at ambient temperature for about 16 hours, and then filtered through a small pad of silica gel. Following standard extractive workup with ethyl acetate, the crude residue was F purified by silica gel column chromatography (ethyl acetate: petroleum ether (1:10)) to give the title product as a colorless N-1 ns oil (2.85 g; yield=57%). H NMR (300 MHz, CDC1) 8: 7.29-7.42 (m, 5H), 4.59 (s. 2H). D Step 3 HO (0162 D D D D

Step 1 O He X.D D 0158

O D D D D

O He- OH Br --- N1 ^x O O D D D D

da-Ethane-1,2-diol 1-((2-Bromo-da-ethoxy)methyl)benzene 0159. A solution of diethyloxalate (6.5 g. 44.48 mmol. (0163 At about -20°C., triphenylphosphine (5.73 g, 21.87 1.00 equiv.) in dry tetrahydrofuran (100 mL) was slowly mmol. 1.20 equiv.) was added in portions, over a period of 15 added to a slurry of lithium aluminum deuteride (1.87 g. minutes, to a solution of d-2-(benzyloxy)ethanol (2.85g. 44.48 mmol. 1.00 equiv) in tetrahydrofuran (100 mL). The 18.24 mmol. 1.00 equiv), and N-bromosuccinimide (4.85g. mixture was heated at reflux for about 3 hours, and then water 27.25 mmol. 1.50 equiv.) in tetrahydrofuran (80 mL). The (4 mL) was added. The solids were removed by filtration, and resulting solution was stirred at 15-25°C. for about 30 min the resulting filtrate was then washed with tetrahydrofuran utes. Following standard extractive workup with ethyl (100 mL). The solvent was removed in vacuo to give the title acetate, the resulting crude residue was purified by Silica gel product as a colorless oil (2.1 g; yield=71%). column chromatography (ethyl acetate/petroleum ether US 2016/01932 12 A1 Jul. 7, 2016 27

(1:5)) to give the title product as a colorless liquid (2.64 g; Step 5 yield=66%). H NMR (300 MHz, CDC1,) 8: 7.31-7.40 (m, 5H), 4.62 (s. 2H) (0166 Step 4

(0164 D O D O D D D O in- -- CrxO X. Br -- 4 vy

O

D HO D D 1 O\ry NH2

2-((3aR.4S,6R,6aS)-6-Amino-2,2-dimethyl-tetrahy dro-3aH-cyclopentad 1.3dioxol-4-yloxy)-di-etha nol 0.167 Under an atmosphere of hydrogen, a suspension of benzyl (3aS.4R,6S,6aR)-6-(2-(benzyloxy)-da-ethoxy)-2.2- dimethyl-tetrahydro-3aH-cyclopentad 1.3dioxol-4-ylcar bamate (2.25 g, 5 mmol. 3.30 equiv.), 10% palladium on carbon (1.6 g. 1.5 mmol. 1.00 equiv.), and methanol (50 mL) was stirred at ambient temperature for about 10 hours. The Suspension was filtered, and the resulting filtrate was concen trated in vacuo to give the title product as a yellow solid (0.95 Benzyl (3aS.4R,6S,6aR)-6-(2-(benzyloxy)-da g; yield=86%). MS: m/z.222 (MH)". ethoxy)-2,2-dimethyl-tetrahydro-3aFI-cyclopentad 1.3dioxol-4-ylcarbamate Step 6 (0165 At about -10° C., benzyl (3aS,4R,6S,6aR)-6-hy (0168 droxy-2,2-dimethyl-tetrahydro-3aH-cyclopentad 1.3di oxol-4-ylcarbamate (3.25 g, 10.57 mmol. 1.00 equiv.) was added to a solution of 70% sodium hydride (0.38 g, 11.11 D NO HO D mmol. 1.05 equiv.) in N,N-dimethylformamide (50 mL). The C C solution was stirred at about -10° C. for about 30 minutes, N and then 1-((2-bromo-da-ethoxy)methyl)benzene (2.64 g. D O NH2 12.04 mmol. 1.14 equiv.) was added. The resulting Solution N N was stirred at ambient temperature for about 24 hours, and 4 Yy St . then water (50 mL) was added. Following standard extractive S workup with ethyl acetate (3x50 mL), the resulting crude O O product was purified by silica gel column chromatography (ethyl acetate: petroleum ether (1:10)) to give title product as l a colorless solid (2.25 g; yield=48%).

US 2016/01932 12 A1 Jul. 7, 2016 30

EXAMPLE 3 Step 2 (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl) 0181 cyclopropylamino)-5-(d-propylthio)-3H-1.2.3 triazolo 4,5-dipyrimidin-3-yl)-5-(2-hydroxyethoxy) O O cyclopentane-1,2-diol (ticagrelor-d) 0178 ---> --- CD O

1n CD3

da-Diethyl 2-methylmalonate 0182. A solution of d-diethyl 2-methylmalonate (48 g. 271.19 mmol. 1.00 equiv.) and triethylamine (27.4g, 271.29 mmol. 1.00 equiv.) in d-methanol (240 mL) was stirred at about 25°C. for about 16 hours. The resulting mixture was then concentrated in vacuo to give the title product as a light yellow liquid (48 g; yield=99%). H NMR (300 MHz, CDC1) 8: 4.16 (q, J–7.2 Hz, 2H), 1.29 (t, J=7.2 Hz, 3H). Step 1 Step 3 0179 0183)

O O O D 1No 1 - 1 So D D CD3 CD

ds-Ethyl propionate 0184. A mixture of d-diethyl 2-methylmalonate (42 g, 235.69 mmol. 1.00 equiv.), sodium chloride (27.5g, 470.57 CD3 mmol. 2.00 equiv.), deuterium oxide (4.8 g. 240.00 mmol. 1.00 equiv.) and dimethylsulfoxide-d (200 mL) was stirred at 150-160° C. for about 3 hours. The solvent was then removed by distillation. Standard extractive workup with ethyl ether d-Diethyl 2-methylmalonate (250 mL) gave the title product, which was used in the next step without further purification (15g, yield=59%), H NMR 0180 Sodium metal (7.59 g, 330.00 mmol, 1.05 equiv.) (300 MHz, CDC1) 8: 4.13 (q, J–7.2 Hz, 2H), 1.25 (t, J=7.2 was slowly added to ethanol (500 mL) and stirred at ambient Hz, 3H). temperature until all the Sodium metal was consumed. At about 0° C., diethyl malonate (50 g, 312.50 mmol. 1.00 Step 4 equiv.) was added dropwise, over a period of 30 minutes, to the stirred solution. At about 0°C., iodomethane-d (47.85g. 0185 330.00 mmol. 1.05 equiv) was then added dropwise, over a period of about 2 hours, to the stirred solution. The solution was stirred at ambient temperature for about 3 hours and then concentrated in vacuo. After adding water (500 mL), standard extractive workup with ethyl acetate (3x300 mL) afforded the title product as a light yellow liquid (48 g; yield=87%). "H CD3 NMR (300 MHz, CDC1) 8: 4.15 (q, J–7.2 Hz, 2H), 2.30 (s, 1H), 1.28 (t, J=7.2 Hz, 3H). US 2016/01932 12 A1 Jul. 7, 2016

ds-Propan-1-ol Step 7 0186. At 0-5°C., lithium aluminum deuteride (5.8 g., 138. (0191) 10 mmol, 0.80 equiv.) was added to a solution of di-ethyl propionate (18.6 g. 173.83 mmol. 1.00 equiv.) in ethyl ether (200 mL). The resulting solution was stirred at ambient tem OH perature for about 3 hours, and then deuterium oxide (50 mL) was added. The solution was stirred at ambient temperature 21y D for about 1 hour, and then the pH value of the solution was D --> adjusted to 4-5 by adding 10% sulfuric acid. The crude prod Sa uct was purified by distillation. The fraction collected was at HO N S D 70-88°C. to give the title product (19.8 g; (crude, contained D D water and ethanol)) as a colorless liquid, which was used in the next step without more purification. OH Step 5 ON 21y D 0187. D N HO N S D D D D D D D HO D I D CD3 CD 5-Nitro-2-(d-propylthio)pyrimidine-4,6-diol 0.192 The procedure of Example 1, Step 12 was followed, but Substituting 2-(propyl-d-thio)pyrimidine-4,6-diol for d7-1-Iodopropane 2-(propylthio)pyrimidine-4,6-diol. The title product was iso 0188 A solution of ds-propan-1-ol (19.8 g. 295.52 mmol. lated as a yellow solid (3.2 g; yield=51%). 1.00 equiv.) in 45% hydroiodic acid (180 mL) was heated at reflux for about 17 hours. The organic phase was separated Step 8 and washed with sodium sulfate (1x10 mL) and brine (1x10 mL). The resulting crude product was then purified by distil 0.193) lation (1 atm). The fraction collected was at 95-101° C. to give the title product as a colorless liquid (5.1 g; yield=26%). OH Step 6 ON 21y D (0189 D --> N HO N S D

OH D D D D D 21 h + I D -- OH

HO N N ls C CD3 ON OH 21y D D S. 21 N D D D C N S D D

HO S.N ls S D D D

2-(d-Propylthio)pyrimidine-4,6-diol 4,6-Dichloro-5-nitro-2-(d-propylthio)pyrimidine (0190. The procedure of Example 1, Step 11, was followed 0194 The procedure of Example 1, Step 13 was followed, but Substituting d7-1-iodopropane for 1-iodopropane. The but Substituting 5-nitro-2-(d-propylthio)pyrimidine-4,6- title product was isolated as an off-white solid (3.5 g; diol for 5-nitro-2-(propylthio)pyrimidine-4,6-diol. The title yield=64%). product was isolated as a yellow oil (1.8 g; yield=49%).

US 2016/01932 12 A1 Jul. 7, 2016 37

-continued -continued

D D D D D D D D US 2016/01932 12 A1 Jul. 7, 2016 38

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 39

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 40

-continued -continued D D D US 2016/01932 12 A1 Jul. 7, 2016 41

-continued -continued

D D D D D D D D US 2016/01932 12 A1 Jul. 7, 2016 42

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 43

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 44

-continued -continued D D D D US 2016/01932 12 A1 Jul. 7, 2016

-continued -continued

D D D D D D D D

D F, HN

D D D N

DC N-X. S l N 2 D D HO- /

US 2016/01932 12 A1 Jul. 7, 2016 46

-continued -continued D D D D D D

US 2016/01932 12 A1 Jul. 7, 2016 47

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 48

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 49

-continued -continued D D D D D D D D

US 2016/01932 12 A1 Jul. 7, 2016 50

-continued -continued D D D D D D

US 2016/01932 12 A1 Jul. 7, 2016 51

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016

-continued -continued D D

F,

D DC

D D %H HO O

D D D D F,

D DC

D D F, %H US 2016/01932 12 A1 Jul. 7, 2016 53

-continued -continued

D D D D D D D D US 2016/01932 12 A1 Jul. 7, 2016 54

-continued -continued

D D D D D D D D US 2016/01932 12 A1 Jul. 7, 2016 55

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 56

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 57

-continued -continued

D D D D D D D D US 2016/01932 12 A1 Jul. 7, 2016 58

-continued -continued

D D D D D D D D US 2016/01932 12 A1 Jul. 7, 2016 59

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 60

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 61

-continued -continued

D D D D D D D D

OH OH HO O HO- /O D

D D D D

D D D D D F s s HN DN F, N N D F HN

US 2016/01932 12 A1 Jul. 7, 2016 67

-continued -continued

HO> / O D

D D

w F, HN

D F N1 S NV DC 2 S N N OH D D %H HO O HO> / O D

D D

D D F, HN F, D F HN

D F N NV US 2016/01932 12 A1 Jul. 7, 2016 68

-continued -continued

HO O HO O

US 2016/01932 12 A1 Jul. 7, 2016 69

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 70

-continued -continued

D D US 2016/01932 12 A1 Jul. 7, 2016 71

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 72

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 73

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 74

-continued -continued D D US 2016/01932 12 A1 Jul. 7, 2016 75

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 76

-continued -continued

D D US 2016/01932 12 A1 Jul. 7, 2016 77

-continued -continued D D D D

US 2016/01932 12 A1 Jul. 7, 2016 78

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 79

-continued -continued D

NS s HN N1S-N F

N-1N S ulN 2 N D

US 2016/01932 12 A1 Jul. 7, 2016 80

-continued -continued D D D D

US 2016/01932 12 A1 Jul. 7, 2016 81

-continued -continued D D D D

US 2016/01932 12 A1 Jul. 7, 2016 82

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 83

-continued -continued

D D

HO O HO O US 2016/01932 12 A1 Jul. 7, 2016 84

-continued -continued

D D D D US 2016/01932 12 A1 Jul. 7, 2016 85

-continued -continued D D US 2016/01932 12 A1 Jul. 7, 2016 86

-continued -continued US 2016/01932 12 A1 Jul. 7, 2016 87

-continued -continued

D D D D US 2016/01932 12 A1 Jul. 7, 2016 88

-continued -continued

D D D D US 2016/01932 12 A1 Jul. 7, 2016 89

-continued -continued

US 2016/01932 12 A1 Jul. 7, 2016 90

-continued -continued

HO O

D D

D D

HO> / O D

D D

D w F, HN

F N1 S NV DC 2 S l N N N OH D D %H HO O

US 2016/01932 12 A1 Jul. 7, 2016 94

-continued -continued D D

D D

HO O

D D

D D

w F, HNS

N F

D D HO> / O HOY K,O D D

D D D D

w F, HNS

N F

US 2016/01932 12 A1 Jul. 7, 2016 97

-continued radation half-life is at least 5%; at least 10%; at least 15%; at least 20%; at least 25%; or at least 30%. NY F, and HN In Vitro Metabolism. Using Human Cytochrome Pso Enzymes N1 N N F 0219. The cytochrome Paso enzymes are expressed from the corresponding human cDNA using a baculovirus expres N-1 ns ul4N sion system (BD Biosciences, San Jose, Calif.). A 0.25 mil OH liliter reaction mixture containing 0.8 milligrams per millili ter protein, 1.3 millimolar NADP", 3.3 millimolar glucose 6-phosphate, 0.4U/mL glucose-6-phosphate dehydrogenase, %H 3.3 millimolar magnesium chloride and 0.2 millimolar of a compound as disclosed herein, the corresponding non-isoto HO O pically enriched compound or standard or control in 100 o millimolar potassium phosphate (pH 7.4) is incubated at 37° D C. for 20 minutes. After incubation, the reaction is stopped by the addition of an appropriate solvent (e.g., acetonitrile, 20% s F. trichloroacetic acid, 94% acetonitrile/6% glacial acetic acid, HN 70% perchloric acid, 94% acetonitrile/6% glacial acetic acid) and centrifuged (10,000 g) for 3 minutes. The supernatant is N1 N N F analyzed by HPLC/MS/MS.

N-1 ns ul 4NI Cytochrome Paso Standard AOH CYP1A2 Phenacetin CYP2A6 Coumarin CYP2B6 'C-(S)-mephenytoin oH CYP2C8 Paclitaxel CYP2C9 Diclofenac HO O CYP2C19 'C-(S)-mephenytoin CYP2D6 (+/-)-Bufuralol > / CYP2E1 ChlorZoxazone D CYP3A4 Testosterone CYP4A 'C-Lauric acid 0217 Changes in the metabolic properties of the com pounds disclosed herein as compared to their non-isotopi cally enriched analogs can be shown using the following Monoamine Oxidase a Inhibition and Oxidative Turnover assays. Compounds listed above which have not yet been 0220. The procedure is carried out using the methods made and/or tested are predicted to have changed metabolic described by Weyler et al., Journal of Biological Chemistry properties as shown by one or more of these assays as well. 1985, 260, 13199-13207, which is hereby incorporated by reference in its entirety. Monoamine oxidase A activity is Biological Activity Assays measured spectrophotometrically by monitoring the increase in absorbance at 314 nm on oxidation of kynuramine with In Vitro Liver Microsomal Stability Assay formation of 4-hydroxyquinoline. The measurements are car 0218 Liver microsomal stability assays were conducted at ried out, at 30°C., in 50 mM sodium phosphate buffer, pH 7.2. 1 mg per mL liver microsome protein with an NADPH containing 0.2% Triton X-100 (monoamine oxidase assay generating system in 2% sodium bicarbonate (2.2 mM buffer), plus 1 mM kynuramine, and the desired amount of NADPH, 25.6 mM glucose 6-phosphate, 6 units per mL glu enzyme in 1 mL total Volume. cose 6-phosphate dehydrogenase and 3.3 mM magnesium Monooamine Oxidase B Inhibition and Oxidative Turnover chloride). Test compounds were prepared as solutions in 20% acetonitrile-water (20 uM stock solutions) and added to the 0221) The procedure is carried out as described in Uebel assay mixture (final assay concentration 1 LM). Final concen hacket al., Pharmacopsychiatry 1998, 31(5), 187-192, which tration of acetonitrile in the assay should be <1%. The reac is hereby incorporated by reference in its entirety. tions were incubated at 37° C. Aliquots (50 uL) were taken out at times 0, 15, 30, 45, and 60 minutes, and diluted with ice Inhibition of Platelet Aggregation cold acetonitrile (200 uL) to stop the reactions. Samples are 0222. The procedure is carried out as described in Husted centrifuged at 12,000 RPM for 10 minutes to precipitate et al., Eur: Heart J. 2006, 27(9), 1038-1047, which is hereby proteins. Supernatants are transferred to microcentrifuge incorporated by reference in its entirety. tubes and stored for LC/MS/MS analysis of the degradation half-life of the test compounds. It has thus been found that certain isotopically-enriched compounds disclosed herein Measuring Pharmacokinetics, and Safety of Ticagrelor that have been tested in this assay showed an increased deg 0223) The procedure is carried out as described in Husted radation half-life as compared to the non-isotopically et al., European Heart Journal 2006, 27(9), 1038-1047, enriched drug. In certain embodiments, the increase in deg which is hereby incorporated by reference in its entirety. US 2016/01932 12 A1 Jul. 7, 2016

Detecting Ticagrelor and Ticagrelor Metabolites in Humans 31. The method as recited in claim 30 wherein said addi tional therapeutic agent is selected from the group consisting 0224. The procedure is carried out as described in Butler, of alpha adrenergic receptor antagonists, beta adrenergic et al., Drug Metab Rev 2008, 40(Suppl. 3): Abst 280, which is receptor antagonists, angiotensin II receptor antagonists, hereby incorporated by reference in its entirety. angiotensin-converting enzyme inhibitors, anti-arrhythmics, Bleeding Time antithrombotics, antiplatelet agents, calcium channel block ers, fibrates, and HMG-CoA reductase inhibitors. 0225. The procedure is carried out as described in Husted 32. The method as recited in claim 31 wherein said alpha et al., Eur: Heart J. 2006, 27(9), 1038-1047, which is hereby adrenergic receptor antagonist is selected from the group incorporated by reference in its entirety. consisting of abanoquil, adimolol, ajmalicine, alfuZosin, amosulalol, arotinolol, atiprosin, benoxathian, buflomedil, Inhibition of Platelet Aggregation bunaZosin, carvedilol, CI-926, corynanthine, dapiprazole, 0226. The procedure is carried out as described in WO DL-017, domesticine, doxazosin, eugenodilol, fenspiride, 2000034283, which is hereby incorporated by reference in its GYKI-12,743, GYKI-16,084, indoramin, ketanserin, L-765, entirety. 314, labetalol, mephendioxan, metaZosin, monatepil, moxi Sylyte (thymoxamine), naftopidil, nantenine, neldaZosin, Inhibition of Platelet Aggregation nicergoline, niguldipine, pelanserin, phendioxan, phenoxy benzamine, phentolamine, piperoxan, praZosin, quinazosin, 0227. The procedure is carried out as described in WO ritanserin, RS-97,078, SGB-1,534, silodosin, SL-89.0591, 199905142, which is hereby incorporated by reference in its spiperone, talipexole, tamsulosin, teraZosin, tibalosin, tioda entirety. Zosin, tipentosin, tolaZoline, trimaZosin, upidosin, urapidil, 0228. From the foregoing description, one skilled in the art Zollertine, 1-PP. adimolol, atipamezole, BRL-44408, buflom can ascertain the essential characteristics of this invention, edil, cirazoline, efaroxan, esmirtazapine, fluparoxan, GYKI and without departing from the spirit and scope thereof, can 12,743, GYKI-16,084, idazoxan, mianserin, mirtazapine, make various changes and modifications of the invention to MK-912, NAN-190, olanzapine, phentolamine, phenoxy adapt it to various usages and conditions. benzamine, piperoxan, piribedil, rauwolscine, rotigotine, 1-25. (canceled) SB-269,970, setiptiline, spiroxatrine, sunepitron, tolazoline, 26. A method of treatment of a P2Y 12 receptor-mediated and yohimbine. disorder comprising the administration, to a patient in need 33. The method as recited in claim 31 wherein said beta thereof, of a therapeutically effective amount of a compound adrenergic receptor antagonist is selected from the group having the structural formula: consisting of acebutolol, adaprolol, adimolol, afurolol. alprenolol, alprenoXime, amoSulalol, ancarolol, arnolol, aro tinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bormetolol, bornaprolol, brefonalol, bucindolol, HNW w F bucumolol, bufetolol, buftiralol, bufuralol, bunitrolol, bunolol, bupranolol, burocrolol, butaxamine, butidrine, buto N F filolol, capsinolol, carazolol, carpindolol, carteolol. N1 S V carvedilol, celiprolol, cetamolol, cicloprolol, cinamolol, clo DC 2 ranolol, cyanopindolol, dalbraminol, dexpropranolol, diac S us N N N etolol, dichloroisoprenaline, dihydroalprenolol, dilevalol, D D OH diprafenone, draquinolol, dropranolol, ecastolol, epanolol. ericolol, ersentilide, esatenolol, esmolol, esprolol, eugeno dilol, exaprolol, fallintolol, flestolol, flusoxolol, hydroxycar 'OH teolol, hydroxytertatolol, ICI-118,551, idropranolol, inde HO O nolol, indopanolol, iodocyanopindolol, iprocrolol. isoxaprolol, isamoltane, labetalol, landiolol, levobetaxolol. D D levobunolol, levocicloprolol, levomoprolol, medroxalol, D D mepindolol, metalol, metipranolol, metoprolol, moprolol. nadolol, nadoxolol, nafetolol, nebivolol, neraminol, nife wherein each position represented as D has deuterium malol, nipradillol, oberadillol, oXprenolol, pacrinolol. enrichment of no less than about 10%, and wherein said pafenolol, pamatolol, pargolol, parodilol, penbutolol. disorder is selected from the group consisting of myo penirolol, PhOA-33, pindolol, pirepolol, practolol, primi cardial infarction, stroke, and acute coronary syndrome. dolol, procinolol, pronethalol, propafenone, propranolol. 27. The method as recited in claim 26 wherein each posi ridazolol, ronactolol, Soquinolol, Sotalol, spirendolol, SR tion represented as D has deuterium enrichment of no less 59230A, sulfinalol, TA-2005, talinolol, tazolol, teoprolol, ter than about 50%. tatolol, terthianolol, tienoxolol, tilisolol, timolol, tiprenolol, 28. The method as recited in claim 26 wherein each posi tolamolol, toliprolol, tribendilol, trigevolol. xibenolol, and tion represented as D has deuterium enrichment of no less Xipranolol. than about 90%. 34. The method as recited in claim 31 wherein said angio 29. The method as recited in claim 26 wherein each posi tensin II receptor antagonist is selected from the group con tion represented as D has deuterium enrichment of no less sisting of candesartan, eprosartan, irbesartan, losartan, olm than about 98%. esartan, tasosartan, telmisartan, and Valsartan. 30. The method as recited in claim 26 further comprising 35. The method as recited in claim 31 wherein said angio the administration of an additional therapeutic agent. tensin-converting enzyme inhibitoris selected from the group US 2016/01932 12 A1 Jul. 7, 2016 99 consisting of captopril, enalapril, lisinopril, perindopril, lirudin, dabigatran etexilate, defibrotide, dermatan Sulfate, ramipril, quinapril, benazepril, cilaZapril, fosinopril, tran fondaparinux, and rivaroXaban. dollapril, spirapril, delapril, moexipril, temocapril. Zofeno 38. The method as recited in claim 31 wherein said anti pril, and imidapril. platelet agent is selected from the group consisting of abcix 36. The method as recited in claim 31 wherein said anti imab, eptifibatide, tirofiban, clopidogrel, prasugrel, ticlopi arrhythmic is selected from the group consisting of quinidine, dine, ticagrelor, beraprost, prostacyclin, iloprost, treprostinil, procainamide, disopyramide, Sparteine, ajmaline, prajma acetylsalicylic acid, aloxiprin, carbasalate calcium, line, lorajmine, lidocaine, mexiletine, tocainide, aprindine, indobufen, dipyridamole, picotamide, terutroban, cilostaZol. propafenone, flecainide, lorcainide, encainide, amiodarone, dipyridamole, triflusal, cloricromen, and ditazole. bretylium tosilate, bunaftine, dofetilide, ibutilidem, tedis 39. The method as recited in claim 31 wherein said calcium amil, moracizine, and cibenzoline. channel blocker is selected from the group consisting of 37. The method as recited in claim 31 wherein said anti amlodipine, felodipine, isradipine, nicardipine, nifedipine, thrombotic is selected from the group consisting of dicouma nimodipine, nisoldipine, nitrendipine, lacidipine, nilvad rol, phenindione, warfarin, phenprocoumon, acenocoumarol, ipine, manidipine, barnidipine, lercanidipine, cilnidipine, ethyl biscoumacetate, clorindione, diphenadione, tiocloma benidipine, mibefradil, Verapamil, gallopamil, diltiazem, rol, heparin, antithrombin III, dalteparin, enoxaparin, nadro fendiline, bepridil, lidoflazine, and perhexiline. parin, parnaparin, reviparin, danaparoid, tinzaparin, Sulodex 40. The method as recited in claim 31 wherein said fibrate ide, bemiparin, ditazole, cloricromen, picotamide, is selected from the group consisting of clofibrate, beZafi clopidogrel, ticlopidine, acetylsalicylic acid, dipyridamole, brate, aluminium clofibrate, gemfibrozil, fenofibrate, simfi carbasalate calcium, epoprostenol, indobufen, iloprost, brate, ronifibrate, ciprofibrate, etofibrate, and clofibride. abciximab, aloxiprin, eptifibatide, tirofiban, triflusal, bera 41. The method as recited in claim 31 wherein said HMG prost, treprostinil, prasugrel, Streptokinase, alteplase, uroki CoA reductase inhibitor is selected from the group consisting nase, fibrinolysin, brinase, reteplase, Saruplase, ancrod, of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevasta drotrecogin alfa (activated), tenecteplase, protein C, desiru tin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. din, lepirudin, argatroban, melagatran, Ximelagatran, biva k k k k k